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PREFACE 
We are obliged to live in an infected world, along with hordes of pathogenic protozoa, 
bacteria, and viruses and their phages. Occasionally, when pathogen and host come 
together infection results. Infections of the respiratory tract are probably the commonest 
of all infections in otherwise healthy people. Symptoms ranging from mild to severe and 
serious illness may result from infection of the respiratory tract by a variety of viral 
and/ or bacterial pathogens. Pulmonary infection may cause severe primary or secondary 
pneumonia with allied conditions and may eventually lead to severely impaired 
pulmonary function with life threatening hypoxemia. Furthermore, respiratory infection 
may cause exacerbations of preexisting disease, especially in patients with preexisting 
respiratory disease, e.g. chronic bronchitis or asthma. 
Specific antibiotic treatment of pneumonia is usually guided by knowledge of the likely 
infecting organism. Apart from specific antibiotic treatment or when antibiotic treatment 
is not effective, e.g. in case of non-influenza! viral pneumonia or due to resistance of the 
microbial agent, therapy is entirely supportive and often requires artificial ventilation. 
This thesis aims at evaluating two "new" concepts for the management of pneumonia. 
The first concept, oral immunization, seems a promising approach towards prevention 
of pneumonia. Extensive programs have been developed for active immunoprophylaxis 
to immunize against specific microbial pathogens, and vaccines introduced into clinical 
practice since the 1970s include those against H. influenzae, meningococs, pneumococs, 
pseudomonas, hepatitis B virus and rabies. However, controversies surrounding 
established vaccines and the search for vaccines against other pathogens constantly 
stimulate investigations on the development of new vaccines. 
Therefore, and because oral administration of vaccines is convenient, much attention has 
been paid to the development of vaccines for oral administration. It is proven that oral 
administration of vaccine of viral or bacterial origin can induce a mucosal immune 
response, but the possibility of oral immunization with bacterial lysate for the prevention 
of viral pneumonia has not been well documented. The first part of this thesis presents 
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investigations on oral immunization with a new polyvalent bacterial lysate against both 
bacterial and viral pathogens that may cause pneumonia. 
The second concept, surfactant replacement therapy, has already proven its value in the 
prevention and treatment of idiopathic respiratory distress syndrome (IRDS) of the 
newborn, which is caused by a surfactant deficient state of the premature lungs. Several 
studies on the origin and nature of the adult respiratory distress syndrome (ARDS) have 
demonstrated a surfactant deficient state of the lungs of ARDS-patients and frrst clinical 
trials of surfactant replacement in ARDS patients have proven the beneficial effects of 
surfactant replacement. Pneumonia may lead to a clinical syndrome closely resembling 
ARDS. Therefore, the second part of this thesis presents investigations on surfactant 
replacement therapy during ARDS-like viral pneumonia. 
- 8-

One 
Overview of the study 
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CHAPTER I 
OVERVIEW OF THE STUDY 
PART I. ORAL IMMUNIZATION 
Chapter 2 
Oral immunization may prove a convenient and effective way for the induction of 
protection against infections. Oral administration of vaccines of viral or bacterial origin -
also referred to as oral immunomodulators - to immunize against infectious disease is 
not widely utilized in the Netherlands. To my knowledge the only oral vaccine currently 
in use in the Netherlands is the oral polio-vaccine. The so-called "common mucosal 
immune system" plays an important role in oral immunization. Therefore, to introduce 
the concept of oral immunization and the mechanisms involved this chapter gives a 
general survey of the "common mucosal immune system" and presents studies on oral 
administration of vaccine. 
Chapter 3 
In this chapter, a new polyvalent bacterial lysate (Paspat oralj for use as an oral 
immunomodulator is presented. The potential efficacy of oral immunization with this 
lysate was studied in a model of intranasal S. pneumoniae infection in mice. 
Chapter 4 
In the previous chapter a significant protective effect of oral immunization with Paspat 
oral .. against S. pneumoniae infection in mice was reported. Thereafter, the pulmonary 
response to oral immunization with Paspat oral.. was investigated by means of 
bronchoalveolar lavage (BAL). Inflammatory changes in BAL fluid were measured 
during oral immunization, before and after infection with S. pneumoniae. Details of the 
study are presented in this chapter. 
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Chapter 5 
In chapter 4 a potential stimulation of nonspecific immune mechanisms by oral 
immunization was reported. To further investigate the potency of this stimulation a study 
was designed in which mice were orally immunized with Paspat oral• and subsequently 
infected with influenza A virus aerosol. Furthermore, the role ofT-helper lymphocytes 
and alveolar macrophages was investigated. 
PART II. SURFACTANT REPLACEMENT THERAPY 
Chapter 6 
A short introduction to pulmonary surfactant is given. Surfactant replacement therapy 
has found its application in the prevention and treatment of the idiopathic respiratory 
distress syndrome (IRDS) in newborns and is currently being investigated for treatment 
of the adult respiratory distress syndrome (ARDS). 
Chapter 7 
Several experimental models have been developed to study the etiology and treatment 
of ARDS. The use of surfactant replacement therapy has been evaluated to a certain 
limit in experimentalARDS-models. Inevitably, variations exist concerning the techniques 
for induction of pulmonary damage and concerning development of the characteristic 
features of ARDS in these models. In this chapter a new model of acute respiratory 
failure, in rats, induced by infection with Sendai virus aerosol, - closely resembling ARDS 
- is presented. 
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Chapter 8 
In the previous chapter a new ARDS model in rats was presented. In this chapter the 
influence of different ventilator settings and surfactant replacement therapy on arterial 
blood gases was measured in the endstage of the infection. 
Chapter 9 
In chapter 8 significant beneficial effects of surfactant replacement therapy during 
endstage respiratory failure during Sendai virus pneumonia were reported. It is 
conceivable that improved gas exchange following surfactant replacement therapy is a 
result of improved pulmonary mechanics. To adequately measure the effects of surfactant 
replacement therapy on pulmonary mechanics it is essential to measure functional 
residual capacity (FRC) and pulmonary compliance. In this chapter the influence of 
influenza A virus infection on pulmonary mechanics is described by measuring FRC and 
thorax-lung compliance in mice. Furthermore, the effects of surfactant replacement 
therapy on pulmonary mechanics was measured in the endstage of the disease. Basically, 
the same experimental model was used as d~scribed in chapter 5. 
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Induction of a mucosal immune response by oral immunization. 
An overview. 
GJ van Daal, B Lachmann 
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CHAPTER II 
INDUCTION OF A MUCOSAL IMMUNE RESPONSE BY ORAL 
IMMUNIZATION. AN OVERVIEW 
Mucosal surfaces, which represent a vast area of contact with the environment, are the 
most frequent portals of entry of viral, bacterial and parasitic disease and other 
environmental antigenic substances. Via this route, antigens of diverse microbial and food 
origin continuously stimulate the entire immune system. Specific humoral as well as cell-
mediated immune responses are continuously induced, not only at the site of stimulation 
but also in draining lymph nodes, spleen and bone marrow. The primary function of the 
immunoglobulins, produced in the mucosal tissues, is to prevent the entry of 
environmental pathogens into the internal milieu. The major mucosal immunoglobulin, 
secretory IgA (sigA) has been shown to be correlated with protection against a variety 
of mucosal pathogens (53). Compared to other immunoglobulin isotypes, slgA does not 
effectively flX complement or promote phagocytosis. These mechanisms, however, except 
for alveolar macrophages, do not to a significant extent operate in external secretions. 
slgA functions as a so called "antiseptic paint" at mucosal surfaces. Invasion of pathogens 
is effectively neutralized by inhibition of the adherence of these organisms to surfaces by 
slgA. 
It would, therefore, seem to be highly desirable to induce protective antibody- and cell-
mediated immunity at mucosal surface (111). Numerous attempts have been made to 
induce immune responses in mucosal tissues, mucosa-associated lymphoid tissues 
(MALT) and external secretions (for review see 80). Mucosal tissues of the respiratory 
tract, conjunctiva, vagina or intestinal tract have been exposed to live or attenuated or 
killed viruses or bacteria in attempt to induce a local immune response and concurrent 
protection against the pathogens under investigation. Considerable attention has been 
paid to the induction of slgA and studies on the origin of IgA-producing cells and routes 
of immunization led to the concept of a so-called "common mucosal immune system". 
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THE "COMMON MUCOSAL IMMUNE SYSTEM" 
The concept of the "common mucosal immune system" describes the relationship 
between gut-associated lymphoid tissue (GALT) and other mucosal tissues and exocrine 
secretory tissues, in which local immunization at one place in the mucosal system also 
induces a humoral immune response at distant mucosal sites. Of all exocrine secretory 
tissues - i.e mucosa and MALT - the intestinal tract is quantitatively the most active 
organ engaged in the immunoglobulin production, particularly those of the IgA isotype 
(32, 81). For example, 70-80% of all Ig-producing cells of the body are located in the 
intestinal mucosa (23, 129). Submucosal B-cells synthesize predominantly J-chain 
containing IgA. It is not fully understood how these phenotypic features are favored by 
the mucosal microenvironments (16). Positive immune regulation must favor the 
development of B-cell clones which can also produce J-chains, because this is a 
prerequisite for external translocation of locally produced immunoglobulins (22). Before 
secretion an additional polypeptide chain, the secretory component (SC), is coupled to 
the dimeric IgA and this complex (secretory IgA, slgA) is transported into external 
secretions (22). 
An important basis for mucosal immunity is the migration so-called "homing" of specific 
B-and T-cells after stimulation with antigen, from BALT and GALT to the submucosa 
and to various other secretory tissues (for reviews see 14 and 80). IgA plasma cells that 
produce antibodies specific for orally administered antigens were also detected in 
extraintestinal lymphoid organs (60). Further investigations revealed that antibody-
forming cells disseminate to other organs after topical application of antigen (87) and 
studies on oral immunization confirmed that in addition to milk, slgA antibodies can be 
induced in secretions of almost all other glands as well ( 40, 82, 139). This "homing" 
phenomenon requires the local presence ofT-helper cells for IgA (is). The nature of 
the "common mucosal immune system" and the induction of a mucosal immune response 
have been the object of many studies on oral immunization. However, the particular 
immunoregulatory requirements of mucosal immunity are still obscure. Under 
appropriate conditions, oral administration of protein antigens may even lead to systemic 
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tolerance (107, 118, 122, 130). Genuine forms of systemic tolerance can be induced by 
oral administration of common antigens like ovalbumin, B-lactoglobulin or erythrocytes 
(3, 108, 140). It is not clear what causes the different immune responses to microbial and 
nonmicrobial antigens but systemic tolerance and mucosal immunity may appear 
concomitantly by development of regulatory antigen-specific suppressor and helper T-
cells after oral immunization (25, 26, 38, 39). Furthermore, it is suggested that MALT 
may be able to discriminate between microbial and nonmicrobial antigens and deviate 
in this respect from its systemic counterpart (140). 
HUMORAL IMMUNE RESPONSE AFTER ORAL IMMUNIZATION 
A sizable number of publications on the induction of mucosal antibody by oral 
immunization has been generated (for review see 10). Most studies were performed in 
rodents and show induction of IgA in external secretions like saliva, colostrum, milk, 
tears, bile and on the mucosal surfaces of the respiratory and female genital tract. 
Antigens of bacterial, viral or other origin have been investigated widely (Table 1). In 
some studies, a concurrent serum response was observed (IgG and IgM) and in some 
cases increased IgG antibodies were also found in mucosal tissues or external secretions 
( 43, 102). Generally it was concluded from these studies that oral administration of 
antigen is an attractive method for the induction of specific mucosal immunity and that 
live vaccines induce a stronger antibody response. Furthermore, that the physical or 
chemical nature of the antigens may be decisive for the strength of the mucosal immune 
response and the type of antibody produced (99). Therefore, ,currently much attention 
is paid to the development of sophisticated antigen-delivery systems for oral 
immunization. 
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Table 1. Mucosal IgA production after oral administration of antigen. 
Antigen Species Tissue/fluid Reference 
S. mutans rat saliva/milk 82,83 
saliva/milk 
S. mutans mouse saliva 26 
E. coli rat milk/lung 56,74 
urine/bile 
P. aeruginosa rat BAL 51 
B. gingivalis mouse saliva 94 
fimbriae 
S. pneumoniae mouse BAL/tear/saliva 88 
C.trachomatis mouse BAL 34 
Gastroenteritis pig milk 20 
virus 
Influenza A mouse BAL/bile 7, 123 
virus monkey nose/saliva 
RSV rabbit milk/gut 102 
Antigen delivery 
Induction of an effective mucosal immune response by the oral route requires relatively 
high doses of antigen due to the digestion of antigens by gastrointestinal enzymes, limited 
absorption of antigens from the gastrointestinal tract and co~pling to preexisting 
antibodies and other substances in the intestinal tract (70, 116, 120, 126). Furthermore, 
oral use of inactivated microbial preparations does not stimulate the immune system as 
strong as live attenuated vaccines (80). Therefore, several approaches to improve antigen 
delivery into the gastrointestinal tract are currently under investigation. Several studies 
report the successful use of cholera toxin to enhance a mucosal uptake of antigen and 
enhanced immune response (11, 38, 66, 121). To protect antigenic determinants from 
acid pH and proteolysis by gastric enzymes, antigens have been given orally in a large 
amount of sodium bicarbonate (17), coatings consisting of gelatin capsules that are 
soluble only in alkaline pH (17, 37, 136) or liposomes, in some cases combined with 
adjuvant (9, 84, 133). From these studies it becomes clear that protection of orally 
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delivered antigens against intragastric degradation significantly improves the delivery of 
antigens into the gut and consequently improves the stimulation of GALT which, in turn, 
significantly enhances the immune response of the mucosal immune system. 
Oral induction of a humoral mucosal immune response in humans 
The evidence for a "common mucosal immune system" in humans is indirect, because 
experiments in which labeled cells from donors are transferred to irradiated syngeneic 
recipients cannot be performed in humans (33). However, substantial information exists 
that indicates that a "common mucosal immune system" is also functionally present in 
humans. Secretions from glands that are not directly stimulated may contain slgA 
antibodies against ingested or inhaled antigen ( 4, 79); this antibody has to originate from 
local production because circulating polymeric IgA is not efficiently transported into 
human external secretions (64). 
Several studies (Table 2) have now demonstrated the possibility of antibody induction by 
oral immunization with vaccines of different bacterial or viral origin in humans. After the 
first successful results with oral immunization obtained with killed bacteria (S. mutans) 
in humans (76, 78), Clancy and coworkers could demonstrate the specific protective 
effect of oral immunization with killed non-typable H. influenzae (NTHI), which reduced 
the colonization with NTHI of patients with chronic obstructive lung disease (COPD) 
concurrently with a reduced incidence of respiratory infection (30, 31). Other studies 
have also investigated the influence of oral immunization on patients prone to frequent 
respiratory infection (Table 3). The overall conclusion from these studies is that oral 
immunization can significantly reduce the number and duration of infectious episodes in 
both infant and adult patients with chronic bronchitis. It is, however, not entirely clear 
whether the protective effects of oral immunization in some of the clinical studies may 
entirely be attributed to antibody induction or whether activated nonspecific immune 
mechanisms also play a significant role. 
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Table 2. Examples of induction of antibody response by oral immunization in humans. 
Antigen 
Bacterial vaccines 
S. mutans 
E. coli 
H. influenzae 
S. typhi 
V. cholerae + 
B-subunit 
Mixed bacterial vaccines 
H. influenzaej 
S. aureus 
vaccine 
polyvalent 
(lysate of 8 
strains) 
ribosomal vaccine 
(from 4 strains) 
Viral vaccines 
Poliovirus 
Rotavirus 
Influenza A 
virus 
Adenovirus 
type 1, 2, 5 
and 21 
Response 
T slgA in saliva, milk and tears 
T lgA and IgM producing cells in blood 
T slgA producing cells in milk 
T slgA in saliva, lgG and lgM response 
in serum 
T slgA in saliva 
T IgA, IgG and IgM producing cells 
in blood no specific antibody in saliva or faeces 
serum antitoxin, lgA, IgG and lgM 
producing cells obtained from blood 
IgA, IgG and IgM antibodies specific for 
H. influenzae in saliva, not in serum. 
No increase in antibodies against S. aureus 
T slgA, ! lgE in saliva 
T lgA, ! IgE in serum, 
T urinary lgA 
antibody-forming cells in tonsils 
T nasal slgA, serum IgG 
T nasal slgA, genital IgG, 
T serum lgA, lgG, lgM 
T milk lgA, milk and saliva slgA 
T serum IgG and lgM (external 
secretions not examined) 
i slgA in saliva, tears and 
nasal secretions 
i coproantibody (IgA), 
neutralizing antibodies in serum 
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Reference 
37, 76,78 
55, 62 
29,30 
63 
68 
28 
36, 45, 
46, 105 
48 
57, 96, 97 
98, 119 
131 
8, 135, 137 
114, 115 
Table 3. Clinical results, in patients with frequent infection of the respiratory tract, obtained with oral 
immunization with different preparations of bacterial origin (trade names). 
Antigen Results 
Patients with recurrent respiratory infection 
Non-typable 
H. influenzae 
Glycoprotein extract 
of K pneumoniae 
(Biostimj 
Ribosomes from 4 
different bacterial 
strains (Ribomunylj 
Lysate from 8 
different bacterial 
strains 
(Broncho-V axom j 
Capsular extract 
from K pneumoniae 
and E. coli 
(Diribiotine CK) 
ENT disorders 
Lysate from 8 
different bacterial 
strains 
(Broncho-V axom j 
! colonization with NTHI and 
of ! incidence of infections in 
patients with COPD 
! exacerbations and l infections 
in patients with stage 2 and 3 
chronic bronchitis 
l number and duration of 
respiratory infections, 
l clinical symptoms 
! clinical symptoms and 
antibacterial therapy, 
i respiratory function in 
infants, adults and elderly 
with chronic bronchitis 
! incidence and duration 
of infectious episodes and antibiotics 
in patients with COPD 
! major symptoms in infants 
and adults with chronic rhinosinusitis 
and chronic purulent sinusitis 
Reference 
30,31 
21, 24,131 
85, 110 
1, 2, 36,41 
45,46,47,54 
69, 71, 77, 100 
109 
58, 113, 144 
NONSPECIFIC EFFECTS OF ORAL IMMUNIZATION 
From the previous sections it becomes clear that oral immunization may enhance the 
specific antiviral or antibacterial resistance of mucosal tissues. Another important issue, 
however, is whether the protective effects observed in studies on oral immunization must 
be attributed to nonspecific immune mechanisms. Nonspecific effects of oral 
immunization may involve activation of innate immunity (50) or enhancement of specific 
rmmune responses by so-called immunological adjuvant present m the 
immunomodulatory preparations (13). Stimulation of nonspecific immune mechanisms 
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like phagocytosis in patients with recurrent respiratory infection may be of equal 
importance as the induction of antibody. Alveolar macrophages (AMs) make up over 
90% of cells in bronchoalveolar lavage fluid (BAL) of normal subjects. These cells form 
the first line of defense against inhaled pathogens, mainly through phagocytosis but also 
through the production and release of lysosomal enzymes, proteases, 0 2 metabolites and 
inflammatory mediators and their function may be affected in patients with COPD (12, 
49). 
Antigen presenting cells (APC's) like macrophages and monocytes can enhance a 
humoral antibody response by presenting antigens on their surface, associated with class 
II molecules of the major histocompatibility complex, to T -helper lymphocytes. 
Presentation of antigen can also be enhanced by addition of adjuvant to a, possibly weak 
antigen to increase its immunogenicity. A long list of natural substances exists which 
increase the activity of weak immunogens, but to date most immunoadjuvants are of 
bacterial origin (for review and list of adjuvants see 134). Adjuvants may theoretically 
enhance antigen presentation through increased expression of Ia antigens or indirectly 
through increased secretion of interferons or interleukins. It is assumed that Freund 
complete adjuvant, presently the most powerful adjuvant, enhances both the expression 
of Ia and the production of interleukin-1 (IL-l) whereas muramyl dipeptide (MDP), a 
synthetic adjuvant originally derived from the cell wall of gram positive bacteria, 
primarily induces high levels of IL-l ( 6). 
However, the use of adjuvants is not without problems and various side effects have been 
reported. Cysts, local granuloma's and the development of tumors were observed with 
the use of adjuvants (90, 95) and the obtained results were conflicting with respect to 
efficacy (106). 
Supposedly by activation of macrophages to a cytotoxic state and induction of lymphokine 
release from macrophages, parenterally administered MDP can induce protection against 
viral, bacterial and fungal infection in different animal models (27, 35, 42, 73, 101, 142, 
143). Adjuvants like murabutide, endotoxic lipopolysaccharide (LPS) and 
monophosphoryl A (MPL) have been shown to directly influence different kinds of cells 
involved in the immune response like B-cells, T -cells, NK cells and macrophages ( 65, 91, 
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93, 89, 124). Although MDP's do not seem to have a direct effect on interferon 
production ( 61, 112), the mechanism of action of adjuvants like MPL and LPS, appears 
to be a direct action on T -helper cells and thereby induction of interferon-gamma (IFN-
gamma) production (93, 124). Nagao and coworkers suggested that MDP injected 
intraperitoneally in guinea pigs stimulates macrophages resulting in the attraction of 
neutrophils (91). Furthermore, apart from stimulation of macrophages, MDP derivates 
augment the IgG antibody response against influenza hemagglutinin and enhance the 
nonspecific resistance against P. aeruginosa (52). Direct adjuvant activity has also been 
described for RU 41740 (Biostim}, a glycoprotein extract from Klebsiella pneumoniae 
(104). In this study RU 41740, given simultaneously during parenteral vaccination of 
elderly (over the age of 65 years) against influenza, significantly increased the specific 
antibody response in otherwise unresponsive volunteers. Considering the nonspecific 
activation of different kinds of cells by oral immunomodulators, adjuvant activity may be 
an important and clinically useful property of oral immunomodulators. 
Several studies have shown changes of cellular activity of macrophages, lymphocytes or 
neutrophils after stimulation with oral immunomodulators in vitro (Table 4) or in vivo 
(Table 5). In general it can be concluded from these studies that oral immunomodulators 
not only show immunological adjuvant activity but induce a multitude of nonspecific 
cellular reactions, including activation of neutrophils, monocytes, macrophages and NK 
cells, and the production of lymphokines and int~rferons. 
Considering the above mentioned, it is not surprising that a few studies have now 
reported possible beneficial effects of oral immunization with different preparations in 
patients with malignancies (5, 18, 67, 138). Increased NK cell activity, increased T-cell 
proliferation, induction oftumor-inhibitorymacrophages, declined T-suppressor cells and 
increased production of interferon and interleukin-2, as reported in these and other 
studies on oral immunization, may significantly contribute in the treatment of 
malignancies. Therefore, immunomodulation for the treatment of cancer by oral 
immunization may become a complementary approach to immunomodulation with 
cytokines like interferon, interleukins and others. 
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Table 4. Effects of in vitro stimulation of cells with oral immunomodulators. 
Cell Effect 
Glycoprotein extract of K pneumoniae (Biostim~ 
Human monocytes t release of antitumor factors 
Murine macrophages t IL-l and TNFa production 
Human PMN's t respiratory burst 
Human neutrophils t chemiluminescence upon stimulation 
Murine bone marrow NK generation from precursors 
precursor cells 
Murine NK cells t of activity 
Lysate from 8 different bacterial strains (Broncho-Vaxom~ 
Macrophages and 
monocytes 
Human peripheral 
blood mononuclear 
cells 
Human T-suppressor 
cells 
t oxidative metabolism, 
t intracellular killing capacity of 
murine peritoneal macrophages 
t TNFa, IL-2 and IFN-gamma 
production, t NK activity 
! antibody-dependent allergic 
autocytotoxicity of white blood cells 
of bronchial asthma patients 
CONCLUDING REMARKS 
Reference 
19 
125 
44 
92 
86 
92, 117 
75 
141 
103 
By comparison with the functions of IgM and IgG, the functions of slgA antibodies do 
not seem very spectacular; nevertheless, under physiological conditions slgA is produced 
in considerable quantities. The function of secretory antibody is to prevent or limit the 
entrance of pathogens into the internal milieu, whereas systemic immunity generally 
removes pathogens from the internal milieu. It is important to realize that the mucosal 
immune system may be exploited in the prevention of infectious disease by stimulation 
with orally applied immunomodulators. Furthermore, it is important to note that other, 
non-humoral immune mechanisms, may significantly attribute to mucosal defense. 
- 24-
Table 5. Effects of oral immunization in vivo. 
Cell Effect 
Glycoprotein extract of K pneumoniae (Biostim~ 
Murine bone marrow 
precursor cells 
Murine NK cells 
l reconstitution of NK cell activity 
after transplantation of bone marrow in 
irradiated mice 
l activity 
Lysates from 8 different bacterial strains (Broncho-Vaxom~ 
Reference 
86 
92,117 
Human lymphocytes 
and macrophages 
l CD4/CD8 ratio and l IFN-gamma 45, 46 
Human lymphocytes 
Human lymphocytes 
production, l total cell counts and 
l macrophageal activity in patients 
with chronic nonobstructive bronchitis 
l T-lymphocyte counts in patients 36 
with chronic bronchitis 
l interferon production by T-lymphocytes, 72 
obtained from infants with recurrent respiratory 
infection 
Lvsates from 7 different bacteria (Paspat oral) 
Rabbit neutrophils 
Murine lymphocytes 
Murine alveolar 
macrophages 
Survival 
of mice 
t oxidative burst after 
stimulation in vitro 
increased pulmonary interferon-gamma 
altered reactivity to stimulation 
with histamine and PGEz, 
l activity after infection with 
influenza A 
Increased survival after intranasal 
infection with S. pneumoniae 
Increased survival after infection 
with influenza A virus aerosol 
59 
Own observations 
submitted 
Own observations 
submitted 
127, 128 
127, Own observations 
submitted 
Enhanced activity of phagocytotic cells, intraepithelial T-lymphocytes and other T-cell 
populations after oral immunization may prove to be of equal importance as the 
induction of antibody in the development of antiviral, antibacteria~ and even antiparasitic 
immunity. Improved antigen packaging, the use of immunological adjuvants and the use 
of synthetic peptides of relevant antigens may improve antigen delivery and significantly 
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reduce the cost of vaccme production. Obviously, oral administration of 
immunomodulators offers attractive possibilities with respect to the simplicity of 
administration of vaccines. Oral immunization circumvents the stringent criteria 
applicable for injectable vaccines and large populations can be simultaneously immunized 
without the assistance of highly trained personnel. Oral immunization may improve our 
chances in eliminating or alleviating severe respiratory, diarrhoeal, and venereal diseases 
that yearly afflict millions of individuals and cause significant mortality both in developed 
and developing countries. Furthermore, enhancement of innate immune mechanisms, like 
stimulation of NK-cells or induction of tumor-inhibitory activity of macrophages, may 
prove effective as an immunomodulatory therapy against malignant disease. 
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CHAPTER III 
ORAL IMMUNIZATION WITH BACTERIAL LYSATE AGAINST 
INFECTION WITH STREPTOCOCCUS PNEUMONIAE IN MICE 
SUMMARY 
The protective effect of oral immunization against infection with streptococcus 
pneumoniae was investigated in mice. Two bacteriallysates, one with an additional lysate 
of C. albicans, were investigated. Intranasal inoculation of adult Balb/c mice with aS. 
pneumoniae type I strain resulted in a lethal infection, with deaths occurring from the 
second day after infection until the sixth day after infection. Oral immunization resulted 
in a significant decrease in mortality rate (18- 48% reduction). No significant difference 
in mortality rates was observed between groups immunized with different lysates, in the 
same concentrations. 
INTRODUCTION 
An important effect of immunization protocols should be enhanced antibody- and cell-
mediated immunity at mucosal membranes, because this large surface area is the porte 
d'entree of the majority of infectious diseases. Repeated attempts have been made to 
develop methods for nonparenteral immunization against viral as well as bacterial 
pathogens in humans [1]. 
Studies on local immunization, using different antigens and routes of administration, 
reported very good local antibody responses [2,3,4,5]. However, this method has many 
practical disadvantages including e.g. the need for aerosol delivery of vaccine, cooperative 
patients and highly trained personnel. 
Studies on oral administration of antigen to protect against intestinal infections have 
resulted in the development of several effective vaccines for the prevention of cholera 
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and typhoid fever [6,7,8]. A significant reduction in acute episodes with fever and 
consumption of antibiotics was described in several studies on oral immunization with 
bacteriallysates in patients susceptible to respiratory infection [9,10,11]. These results 
suggest that it is possible to immunize against respiratory pathogens, circumventing the 
adverse reactions often accompanying parenteral immunization. 
The aim of this study was to investigate whether oral administration of a bacterial lysate 
has any protective effect in mice infected with a high dose of S. pneumoniae, using the 
respiratory tract for inoculation. Further, to investigate whether the addition of C. 
albicans has any influence on the protective effect of the bacterial lysate in this model 
of respiratory infection in mice. 
MATERIALS AND METHODS 
Animals. 
125 Male Balb/c mice (mean body weight 25.3 ± 2.1 g) from Harlan/CPB (Zeist, The 
Netherlands) were used. Animals were kept under conventional conditions; food and 
water were given ad libitum. 
Infection procedure. 
Animals were anesthetized by placing theni in a container, through which a mixture of 
nitrous oxide and oxygen (2:1) with 1.5% halothane was led. 
Inoculation was performed intranasally by holding the mice vertically while the bacterial 
suspension was applied dropwise into the nostrils [12]. All animals were infected with 
0.05 ml from the same bacterial suspension, to prevent differences in size and quantity 
of the inoculum. Animals fully recovered within two minutes after application of the 
inoculum. 
Bacteria. 
AS. pneumoniae type I strain (ATCC 6301) was used in all investigations. This strain 
was selected for its pathogenicity for Balb j c and NMRI mice. Bacteria were grown on 
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mucin blood agar plates, lyophilized aud stored in batches of 6.8x107 colony forming units 
( cfu) at 4° C. On the day of inoculation, 1 ml sterile water was added to one of the 
batches before use. 
Immunization aud challenge scheme. 
Two bacteriallysates {LW 50020 A and Paspat oraf; Luitpold-Werk, Munich, FRG} 
containing lysates of at least 1010 of each of the following bacteria per g: S. aureus, S. 
pneumoniae, S. pyogenes, S. viridaus, K. pneumoniae, B. catarrhalis and H. influenzae 
were used in two different concentrations. 
L W 50020 A contains an additional lysate of C. albicans, which is currently being 
considered as a possible adjuvaut for immunomodulator, whereas Paspat oral• is without 
C. albicaus. The spray-dried lysates were resuspended in sterile saline before application. 
Anesthetized auimals received 0.1 ml of the suspension after intraesophageal 
catheterization. Control animals were sham-immunized with 0.1 ml saline. 
Application was done on days 1, 2 aud 3 followed by a second challenge period on days 
7, 8 aud 9. The auimals were inoculated on day 10 followed by a 14 day observation 
period. 
Immunization protocol. 
Immunization with LW 50020 A resulted in the following groups: 
I 19 animals immunized with 12.5 mg doses 
II 19 auimals immunized with 6.25 mg doses 
III 15 controls, receiving saline 
Immunization with Paspat oral• resulted in the following groups: 
IV 23 animals immunized with 12.5 mg doses 
V 24 animals immunized with 6.25 mg doses 
VI 23 controls, receiving saline 
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Statistical analysis. 
Statistical evaluation of collected data was performed using Fisher's exact test. Statistical 
significance was accepted at P !> 0.05 (two-tailed). 
RESULTS 
At the end of the immunization period no differences in bodyweight, behaviour or 
appearance existed between treated and control groups. 
Deaths occurred from the second until the sixth day after inoculation. The loss of 
bodyweight was linear and significant from the first day after infection to the respective 
moments of death. In both the treated and untreated groups deaths occurred on almost 
the same days. Surviving animals remained unchanged and showed no signs of morbidity 
whatsoever. 
Figure 1 shows survival rates for the different groups. In the group receiving 12.5 mg L W 
50020 A the mortality rate (5%) proved to be significantly lower than in the control 
group (53%), while mortality rate in the group receiving 6.25 mg doses (42%) was not 
significantly different from the control group. Both groups (12.5 and 6.25 mg) receiving 
Paspat oral• showed a significantly decreased mortality rate (13 and 25% respectively) 
when compared with controls (43%). 
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Figure 1. Survival rates (%) of mice immunized with different concentrations of LW 50020 A and Paspat 
oral•, 14 days after infection with S. pneumoniae. * indicates p !f 0.05 Fisher's test, immunized group 
compared to controls. 
DISCUSSION 
This study indicates that animals can be protected against high-dose infection with S. 
pneumoniae by oral immunization with a bacterial lysate. The protective effect might be 
dose-dependent, because higher lysate concentrations resulted in increased protection in 
this study. Scientific acceptance of oral immunization is limited because results often 
seem to be contradictory. Several studies reported the induction of genuine forms of 
systemic tolerance after oral feeding of antigens like ovalbumin, B-lactoglobulin or 
erythrocytes [13,14,15]. Systemic tolerance and mucosal immunity may appear 
concomitantly after oral immunization and antigen feeding is associated with the 
development of regulatory antigen-specific suppressor and helper T-cells [16,17]. The 
type of antigen may also play an important role because a difference in mucosal 
immunogenicity between bacterial and food antigens has been reported [15]. 
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Most orally applied immunomodulators, currently used in many countries, are developed 
empirically and consist of crude lysates of one or more different bacteria or bacterial 
components. Also, concentrations and treatment protocols may differ widely. 
The concentrations of the bacterial lysate used in this animal study are relatively high 
compared to concentrations generally used in humans and, therefore, may not be of 
comparable clinical relevance. Nevertheless, we aimed to achieve a maximal protective 
effect of oral immunization because the inoculum concentration was also very high 
compared to clinical situations. Several groups are currently investigating the combination 
of various adjuvants, like cholera toxin B unit or avridine [17,18] with antigens to enhance 
the protective effects of oral immunization. 
There were no significant differences in mortality rate between groups immunized with 
L W 50020 A or Paspat oral• at the same concentrations, therefore it seems that addition 
of C. albicans does not result in increased protection against S.pneumoniae and thus can 
be excluded from the lysate. 
The protective effect of oral immunization against S. pneumoniae might be explained 
in two ways. First, oral immunization with so called immunomodulators, containing 
various combinations of bacterial and viral antigens, causes priming of precursor cells in 
the gut and the subsequent occurrence of specific secretory IgA (S-IgA) antibody in 
saliva, milk, tears and the respiratory and genital tracts [19,20,21]. As immunological 
cross-activity between antigens of the streptococci in the bacterial lysate and the S. 
pneumoniae used for inoculation was not tested in this study we cannot assess whether 
this plays a role in the protective mechanism observed in these investigations. 
Second, gamma-interferon is thought to have an active role in the nonspecific defense 
against respiratory tract pathogens. Natural killer cells might be stimulated through a rise 
in interferon titer as observed after oral immunization in lung lavage fluids and lung 
tissues [22]. Polyvalent bacteriallysates can induce interferon production by lymphocytes 
in vitro [23]. 
One of these mechanisms, an increase in S-Ig A or an increase in interferon titers, or 
both, might explain the observed protective effect of oral application of the lysates in this 
study. Because second challenge with antigens in humans produced high titers of S-Ig A, 
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which lasted for at least three months [24], we used an immunization scheme that 
contained two separate periods for application of the bacterial lysate in mice. 
It is concluded that oral application of the bacterial lysate used in this study can protect 
mice against infection with S. pneumoniae. Further investigations are needed to elucidate 
the exact mechanism of oral immunization against bacterial respiratory pathogens. 
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CHAPTER IV 
INFLUENCE OF ORAL IMMUNIZATION AND INFECTION WITH 
S. PNEUMONIAE ON INTERFERON-GAMMAAND PMN-ELASTASE 
CONCENTRATIONS IN MURINE BRONCHOALVEOLAR LAVAGE 
FLUID 
SUMMARY 
Oral immunization with a polyvalent bacterial lysate (Paspat oralj can significantly 
reduce mortality rates in mice, infected with S. pneumoniae or influenza A virus. In this 
study it is demonstrated that oral immunization with the same bacterial lysate reduces 
the pulmonary inflammatory reaction to infection with S. pneumoniae. Furthermore, it 
is demonstrated that oral immunization increases pulmonary IFN-gamma production. 
INTRODUCTION 
We recently demonstrated that oral immunization with a bacterial lysate can significantly 
reduce mortality in mice infected with S. pneumoniae [1, 2] or influenza A virus [2]. One 
of the protective mechanisms of oral immunization, apart from induction of specific 
immunity [for review see 3], might be limitation of the alveolar inflammatory reaction 
after infection and thereby reduction of pulmonary damage. Furthermore, it is claimed 
that immunomodulators for oral application enhance nonspecific innate defense 
mechanisms at various sites, including the lungs [4-13]. Emmerich and coworkers have 
reported increased interferon-gamma (IFN-gamma) concentrations and less damage to 
pulmonary tissues due to reduced pulmonary inflammatory reactions in the lungs of 
patients with chronic bronchitis, following oral immunization with a polyvalent bacterial 
lysate [3, 4]. Considering the immunoregulatory properties of IFN-gamma [14-16], we 
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designed a study to investigate whether oral immunization increases pulmonary IFN-
gamma production and concurrently reduces the inflammatory reaction in mice after 
infection with S. pneumoniae. 
MATERIALS AND METHODS 
Male Balb/c mice (n=120; bodyweight 22.1 ± 0.8 g, from Harlan/CPB, Zeist, The 
Netherlands) were randomly assigned to twelve groups. Eight groups were treated with 
a polyvalent bacterial lysate (Paspat oral•, Luitpold-Werk, Miinchen, FRG) [13]; four 
groups served as controls and were sham-immunized with 0.1 ml saline. Anesthetized 
mice (N20:02 2:1 with 1.5% halothane) daily received 12.5 mg or 6.25 mg of the lysate, 
dissolved in 0.1 ml sterile saline, via an intraesophageal tube. Application was done on 
days 1, 2 and 3, and again on days 7, 8 and 9. 
Intranasal infection with of S. pneumoniae (Type I, ATCC 6301, > LD100) was done on 
day 10. On four occasions, twice before (days 5 and 10) and twice after (days 12 and 14) 
infection, three groups (one 12.5 mg group, one 6.25 mg group and one control group, 
n=10/group) were lavaged according to the following protocol. Animals were 
anesthetized (pentobarbitone sodium 60 mg/kg i.p.), tracheotomized and a small metal 
cannula was inserted. Lavage was done three times with a total of 3 ml sterile saline 
preheated to body-temperature (average recovery 2.4 ± 0.1 ml). Bronchoalveolar lavage 
(BAL) fluid was centrifugated and cells were collected for total cell count and evaluation 
of macrophages, lymphocytes and granulocytes concentrations. 
IFN-gamma concentrations in BAL fluid were measured with a solid phase enzyme-
linked immunosorbent assay (ELISA); units are defmed according to NIH standard 
number Gg 02-901-533 [17], one unit corresponds with 500 pg pure recombinant murine 
IFN-gamma. The detection level of the IFN-gamma ELISA was 3U jml. PMN-elastase 
concentrations in BAL were measured with an ELISA for the specific determination of 
elastase from polymorphonuclear leukocytes (PMN's) in complex with alpha-1 proteinase 
inhibitor [18]. 
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RESULTS 
Cell count data are shown in Table 1. Immunization did not significantly change the total 
amount of cells recovered from the lung; neither did it influence concentrations of 
subpopulations (Table 1). IFN-gamma measurements are summarized in Figure 1. After 
the first immunization period IFN-gamma concentrations in BAL fluid were significantly 
higher in both immunized groups and increased even further after the second 
immunization period, whereas all concentrations in the control groups were below the 
detection level. Infection with S. pneumoniae did not influence the quantity of IFN-
gamma recovered. 
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Figure 1. IFN-gamma concentrations (mean :!: SD) in BAL fluid before and after infection. Due to technical 
problems only three samples per group could be measured on day 14, therefore levels of statistical significance 
could not be reached. The detection level of the ELISA is 3 U /mi. All controls remained below the detection 
level. * indicates p ~ 0.05 compared to controls, Mann-Whitney U test. 
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Table 1. 
Total number of cells in BAL (x 100.000) 
DayS Day 10 Day 12 Day 14 
125 mg 6.2 75 S.2 4.2 
(45) (9.3) (4.4) (3.7) 
6.25 mg L3 2.3 S.2 25 
(0.7) (3.0) (4.1) (0.8) 
controls 1.0 1.4 2.0 2.3 
(0.2) (0.7) (0.8) (2_w) 
MacroJ2hages (%) 
DayS Day 10 Day 12 Day 14 
125 mg 68.0 79.2 S4.3 76.4 
(27.7) (18.4) (20.8) (12.2) 
6.25 mg 88.8 83.9 685 80.8 
(6.3) (17.6) (185) (4.6) 
controls 89.3 82.7 60.8 73.4 
(1.6) (10.8) (18.1) (19.9) 
LymJ2hocvtes (%) 
DayS Day 10 Day 12 Day 14 
125 mg 11.3 8.3 175 17.8 
(6.2) (3.7) (6.0) (7.0) 
6.25 mg 8.4 8.6 14.6 1S.O 
(2.9) (2.9) (10.3) (3.6) 
controls 8.9 9.3 12.6 19.3 
(15) (4.1) (4.8) (10.3) 
PMN's (%) 
DayS Day 10 Day12 Day 14 
125 mg 21.3 14.0 28.1 4.6 
(28.0) (20.0) (1S.6) (3.3) 
6.25 mg 2.9 7.2 17.9 3.8 
(S.1) (14.2) (13.1) (2.0) 
controls 1.8 S.8 27.1 7.1 
(0.8) (8.8) (11.4) (7.2) 
Cells (mean ± SD) in BAL fluid from orally immunized mice (125 mg, 6.25 mg and controls) on two 
moments before (days S and 10) and two moments after infection (days 12 and 14) with S. pneumoniae. 
Infection of the day 12 and day 14 groups was done on day 10. No significant differences were observed. 
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PMN-elastase measurements are summarized in Table II. Before infection, 
concentrations in all groups were below the detection level. Two days after infection (day 
12) PMN-elastase concentration was still undetectable in the group immunized with the 
highest lysate dose (12.5 mg). In the other two groups (6.25 mg and controls), however, 
concentrations were significantly higher. On the fourth day after infection (day 14), 
concentrations were still below detection level in the group immunized with the high 
lysate dose and concentrations in the group immunized with the low lysate dose were 
significantly lower compared to controls. 
Table 2. 
DayS Day 10 Day 12 Day14 
12.5 mg nd nd nd • nd • 
6.25 mg nd nd 23.2 2.5 • 
(1.8) (3.5) 
controls nd nd 17.5 17.0 
(16.8) (6.9) 
PMN-elastase (mg/ml) in BAL fluid from orally immunized mice (12.5 mg, 6.25 mg and controls) on two 
moments before and two moments after infection with S. pneumoniae. nd = nondetectable, mean (SD), • 
indicates p :S 0.05 compared to controls, Mann-Whitney U test. 
DISCUSSION 
Oral immunization had no significant effect on concentrations of subpopulations of cells 
in BAL fluid, which is consistent with the findings of other workers in chronic bronchitis 
patients [4]. However, an increase in the helper/suppressor T lymphocyte ratio, mainly 
due to decreased CDS+ cell concentrations, was observed in BAL fluid after oral 
immunization, which might increase activity ofT-helper cells [4]. This might account for 
the increased IFN-gamma concentrations in BAL fluid after oral immunization in this 
study and other studies on oral immunization [4, 5] 
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The interferon system is an integral part of the defense system of the body, mediating 
a large variety of biological effects whereas IFN-gamma has potent immunoregulatory 
effects on a variety of cells. Increased alveolar concentrations of IFN-gamma after oral 
immunization, as observed in this study, suggest enhancement of nonspecific pulmonary 
immunity which might result in increased antibacterial and antiviral capacity of the 
pulmonary defense system. IFN-gamma has antiviral properties [19-21] and can also be 
considered a lymphokine, since it is exclusively a product of lymphocytes upon 
stimulation by antigen-presenting cells. IFN-gamma is a potent macrophage-activating 
factor which might significantly attribute to pulmonary defense after oral immunization 
[4, 22, 23]. T-helper cells are considered the main producers [24, 25]. Therefore, to 
evaluate the induction of nonspecific defense mechanism of the respiratory tract by oral 
immunization, we measured IFN-gamma concentrations in BAL fluid. Simultaneously we 
demonstrated that oral immunization can reduce the pulmonary inflammatory reaction 
after infection with S. pneumoniae. The inflammatory reaction can damage the alveolar 
membrane and the intensity of alveolitis during pulmonary infection can be assessed by 
measurement of PMN-elastase in BAL fluid [26]. Although normally macrophages are 
the resident alveolar phagocytic cells, pulmonary infection causes influx of PMN's. 
Proteolytic enzymes, like PMN elastase, have the potential to destroy the elastin as well 
as the other macromolecular components of pulmQnary extracellular matrix [26]. 
Disruption of the epithelial barrier of the lung by proteolytic enzymes may allow invading 
mechanisms, in this case S. pneumoniae, to penetrate the interstitium and migrate into 
the bloodstream more easily. A similar effect was observed during P. aeruginosa infection 
in guinea pigs [27]. Other groups reported that orally applied immunomodulators 
increase the oxidative burst of stimulated peripheral blood PMN's [6, 11, 13, 21]. 
Infection would thus result in increased PMN-elastase production in immunized animals. 
Our, seemingly contradictory, observations might be attributed to either different reaction 
of PMN's to different stimuli or to a compartimentalization of the effects of oral 
immunization because in this study alveolar PMN-elastase was measured. 
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Summarizing, we conclude that oral immunization with a bacterial lysate reduces the 
pulmonary inflammatory reaction after infection with S.pneumoniae and simultaneously 
may enhance nonspecific pulmonary defense mechanisms by increasing IFN-gamma 
production. 
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CHAPTERV 
PROTECTION AGAINST INFLUENZA A VIRUS INFECTION IN 
MICE BY ORAL IMMUNIZATION WITH A BACTERIAL LYSATE 
SUMMARY 
A study is presented which investigated whether oral immunization with a polyvalent 
bacterial lysate (Paspat oralj can sufficiently enhance cell-mediated defense 
mechanisms to protect mice against influenza A virus infection. It was found that oral 
immunization reduced mortality due to influenza A infection with 15-70%, depending on 
the quantity of virus administered and the moment of infection. Cyclosporin A severely 
reduced the protective effect of oral immunization, suggesting that a major effect of oral 
immunization in these studies is T-cell activation. The effect of oral immunization on 
macrophageal activity was evaluated by measuring cyclic-AMP in alveolar macrophages 
(AMs) obtained by bronchoalveolar lavage. Before infection, basal activity levels of AMs 
in immunized mice were significantly lower than in controls. Five days after infection, 
however, basal activity level of AMs in immunized mice was significantly higher than AM 
activity in controls. Stimulation of AMs with PGE2 significantly reduced cellular activity 
in both groups, before and after infection. However, cellular activity of AMs from 
immunized animals was less reduced than cellular activity of control macrophages. 
Activity of AMs of immunized animals was significantly more reduced by histamine than 
activity of control macrophages. It is concluded that oral immunization with Paspat oral• 
stimulates T cell dependent immune mechanisms, resulting in protection against 
influenza A virus infection in mice. 
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INTRODUCTION 
Apart from parenteral immunization protocols, alternative approaches have been 
considered extensively. Studies on local immunization, using different antigens and routes 
of administration (e.g. aerosols or nasal sprays), result in a very good local antibody 
response [Ganguly, Ogra, Regas & Waldman (1973); Schwartz, Toyo & Hornick (1974)]. 
Besredka introduced oral administration of antigen to protect agamst intestinal infections 
[Besredka (1927)]; this concept has led to the development of several effective vaccines 
for the prevention of cholera [Clemens, Sack, Harris, Chakraborty, Khan, Stanton, Kay, 
Khan, Yunus, Atkinson, et al. (1986)] and typhoid [Germanier (1984)] fever. Oral 
challenge with so-called immunomodulators, containing various combinations of bacterial 
and viral antigens, results not only in the occurrence of specific slgA antibody in the 
intestinal tract [Ogra & Karzon (1969)] but also in saliva [Michalek, McGhee, Mestecky, 
Arnold & Bozzo (1976)], milk [Hanson, Ah~stedt, Andersson, Carlsson, Cole, Cruz, 
Dahlgren, Ericsson, Jalil, Kahn, Mellander, Schneerson, Svanborg Eden, Soderstrom & 
Wadsworth (1983)] and mucous membranes of the respiratory [Clancy, Cripps, Husband 
& Buckley (1983)] and urogenital [Mestecky (1987)] tracts. We recently demonstrated 
that Balb j c mice are protected against a lethal infection with S. pneumoniae (Type I) by 
oral immunization with a polyvalent bacterial lysate [Van Daa~ de Jong, Tenbrinck, 
Mouton, Petzoldt, Bergmann & Lachmann (1990); Van Daa~ So, Mouton, Van 't Veen, 
Tenbrinck, Bergmann & Lachmann (1990)]. 
Furthermore, we recently demonstrated that oral immunization significantly increases 
IFN-gamma production in the lung [submitted] which was also described in other studies 
on oral immunization [Emmerich, Emslander, Pachmann, Hallek, Milatovic & Busch 
(1990a); Emmerich, Emslander, Milatovic, Hallek & Pachmann (1990b)]. Therefore, it 
can be concluded that oral immunization has a direct influence on the activity of several 
types of cells involved in the immune response. 
Already in the mid-Seventies, Raettig observed that the most important advantages of 
oral immunization are its nonspecific effects. He reported that mice can be protected 
against infection with a virulent strain of S. typhimurium by oral immunization with a 
- 66-
heat-inactivated strain of S. enteridis [Raettig (1975)]. Altogether, these results suggest 
enhancement of both antibody-and cell-mediated defense mechanisms by oral 
immunization. 
Therefore, we designed a study to investigate whether oral immunization with a 
polyvalent bacterial lysate can sufficiently enhance cell-mediated defense mechanisms to 
protect mice against influenza A virus infection. 
MATERIALS AND METHODS 
Animals 
The experiments were carried out in 6-8 week old (SPF, 18.0 - 23g) male Balb / c or 
Swiss-bred mice obtained from Harlan/CPB (Zeist, The Netherlands). Animals were 
kept under conventional conditions; food and water were given ad libitum. Bodyweight 
was registered each day at the same time during the entire immunization period and 
during twenty days after the day of infection. 
Virus 
The influenza virus (A/PR8/34, H1N1) used, was pas&ed once in 10 day embryonated 
chicken eggs. The allantoic fluid was clarified by centrifugation and stored at -70° C in 
small aliquots. The stock solution was diluted in sucrose and had a hemagglutination 
(HA) titer 1:400. 
Treatment protocol 
A polyvalent bacterial lysate [Helmberg, Bock, Wolf & Wick (1989)] (Paspat oral'"; 
Luitpold-Werk, Munich, FRG) was applied in three different concentrations. The lysate 
contains at least 1010 of each of the following bacteria per g: Staphylococcus aureus, 
Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus viridans, Klebsiella 
pneumoniae, Branhamella catarrhalis and Hemophilus influenzae. The mechanically 
disintegrated bacteria were resuspended in sterile saline before application. For 
intraesophageal catheterization, animals were anesthetized by placing them in a container 
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through which a mixture of oxygen and nitrous oxide (1:2), containing 1% halothane, was 
led. Animals received 0.1 ml of the suspension through this catheter. Control animals 
were sham-immunized with 0.1 ml saline. Animals recovered within 2 min after this 
procedure. Application was done on days 1, 2 and 3 followed by a second application 
period on days 7, 8 and 9. Animals were infected on day 10 or 24, followed by a 20 day 
observation period. 
Infection procedure 
All animals were exposed once, at the same time, to nebulized live influenza virus 
suspension in an llliter multichamber aerosol box [Loosli, Robertson & Puck (1943)]. 
Aerosol was produced with an Ultravent nebulizer (Ultravent, Malinckrodt Diagnostica, 
The Netherlands) with a flow of 5 ljmin. This device produces particles with a size of 
0.6 - 2 J.Lm [Dahlback, Nerbrinck, Arborelius & Hansson (1983)], which allows for 
deposition of the particles in the peripheral airways and alveoli [Brain & V alb erg (1979) ]. 
Five studies were performed 
Study 1. The effect of oral immunization against a high-dose influenza A virus infection 
was tested. Eighty male BalbI c mice were randomly divided into four groups and treated 
daily with 6.25 mg, 12.5 mg or 25 mg Paspat oral• whereas controls were sham-
immunized with saline according to the above mentioned scheme. On day 10 the animals 
were challenged for 10 min with influenza virus, 1:80 dilution in PBS of stock solution 
(> LDloo)· 
Study 2. A low virus dose was applied. Sixty-eight male BalbI c mice were randomly 
divided into four groups and immunized in the same way as described in study 1. On day 
10 the animals were challenged for 10 min with influenza virus, 1:160 dilution of stock 
solution in PBS ( ± 0.5x LD100). 
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Study 3. The long-term protective effect of oral immunization against a high-dose of 
influenza infection 1:80 dilution in PBS of stock solution ( > LD100) was investigated to 
establish whether the protective effects would persist. Thirty-one male Balb / c mice were 
randomly divided into two groups and treated daily with 25 mg Paspat oral• or saline. 
After the nine-day immunization period, animals were stored for two weeks in a separate 
room to avoid contact with antigen and were challenged fourteen days after the 
immunization period (day 24). 
Study 4. The effect of immuno-suppression by Cyclosporin A (CyA) on the course of a 
high-dose influenza infection was tested in orally immunized animals and controls. This 
study was performed to evaluate the significance ofT -cells in the protective mechanisms 
against influenza virus, activated by oral immunization. Sixty male Swiss-bred mice were 
randomly divided into four groups. Two groups were treated with 25 mg Paspat oral• 
dosages, of which one group received additionally 100 mgjkg CyA solved in olive oil 
(1:10) subcutaneously every other day, starting one day before infection. Two sham-
immunized groups served as controls: of which one group received CyA in the same way 
as the immunized group treated with CyA. All animals were challenged directly after the 
immunization period (day 10) with a high-dose influenza virus, 1:80 dilution in PBS of 
stock solution (> LD100). 
Study 5. The effect of oral immunization on lung function was evaluated. Thorax-lung 
compliance, protein concentrations in broncho-alveolar lavage (BAL) fluid, surface active 
properties of BAL fluid and cellular activity of alveolar macrophages (AMs) were 
measured directly after the immunization period (day 10) and five days after infection 
(day 15) with a high-dose influenza virus, 1:80 dilution in PBS of stock solution ( > 
LD100). Eighty male Balbjc mice were randomly divided into four groups. Two groups 
were treated daily with 25 mg Paspat oral• whereas two groups served as sham-
immunized control groups. Directly after the immunization period (day 10) thorax-lung 
compliance was measured in one immunized group and one control group without being 
infected. Next, BAL was performed three times with 1 ml sterile saline (total 3 ml), 
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preheated to body temperature (average recovery 2.4 ± 0.1 ml). Also, on day 10, one 
immunized group and one control group were infected with a high-dose influenza virus 
1:80 dilution in PBS of stock solution ( > LD100). On the ftfth day after infection (day 15), 
thorax-lung compliance was measured and lung-lavage was performed. 
Lung mechanics 
For measuring lung mechanics, animals were anesthetized by intraperitoneal injection of 
40 mg/kg pentobarbital (Nembutal•, Algin BV, Maassluis, The Netherlands) and 
tracheotomized, using a metal cannula as tracheal tubing. The mice were paralyzed by 
intramuscular injection of 0.05 ml pancuronium bromide (Pavulon•, Organon Technika, 
Boxtel, The Netherlands), transferred to a multichambered body plethysmograph 
[Lachmann, Grossmann, Nilsson & Robertson (1981)] heated to 38° C, and connected 
to a ventilator system for pressure-controlled ventilation. The initial ventilator frequency 
was set at 30/min, I/E ratio 1:2, peak pressure 15 em H20 and Fi02 = 1; the mice were 
ventilated under these circumstances for 5 min to allow stabilization. Then thorax-lung 
compliance was recorded at a frequency of 6/min. 
Macrophageal activity 
The effect of oral immunization on macrophageal activity was evaluated by measuring 
cyclic-AMP (cAMP) in AMs obtained by BAL. A rise in macrophageal intracellular 
cAMP levels is reflected by a reduction in cellular activity [Beusenberg, Adolfs, Van 
Schaik, Van Amsterdam & Bonta (1989)]. Basal cellular activity levels and reactivity to 
stimulation with the inflammatory mediators prostaglandin E2 (PGE2) and histamine 
were measured. Activity was measured according to the following protocol. BAL was 
flltered through surgical gauze and BAL cells were recovered from the lavage fluid by 
centrifugation (800 x g, 10 min at 4° C) and were resuspended in Gay Balanced Salt 
Solution (pH 7.4); thereafter a Ficoll-Isopaque gradient centrifugation was carried out 
(400 x g, 30 min at 4°C). 
Milliliter samples containing 2.10S macrophages were incubated for 15 min at 37° C in 
the presence of 400 J.I.M IBMX (a phosphodiesterase inhibitor), 10·5 M PGEz or 10"4 M 
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histamine. After incubation the cAMP concentrations (expressed as pmoljl.l(f cells) 
were determined using a high-affinity protein binding method [Bonta, Adolfs & Fieren 
(1984)]. Total protein concentrations of BAL fluid were measured with the Biuret 
method [Doumas, Bayse, Borner, Carter, Peters & Schaffer (1981)]. 
Surfactant activity [Clements (1957)] in BAL fluid was measured with a modified 
Wilhelmy balance (Biegler Electronic, Vienna, Austria) by applying 400 J..Ll of BAL fluid 
onto a 71.3 cm2 trough. For measuring minimal surface tensions the area was compressed 
to 20% of the initial value. 
Statistical analysis and data presentation 
Statistical evaluation of collected data was performed using the Kaplan-Meier method 
(product-limit survival estimates) for survival rate curves [SAs• User's guide (1985)] or 
the Mann-Whitney U-test for analyzing between-groups differences. Statistical 
significance was accepted at p ~ 0.05 (two-tailed). All data are expressed as mean ± SD. 
RESULTS 
Study 1. Deaths occurred from 6- 14 days after infection. Figure 1 shows survival rates 
for the different groups until day 16 after infection; no more animals died after this 
period. Survival was significantly improved (15 - 70%) in all three immunized groups 
compared to the control group. 
Study 2. No animals died in the immunized groups, except for one animal in the 12.5 mg 
dose group which died on day 17 after infection (figure 2). In the control group, deaths 
occurred from 9 - 16 days after infection, whereas 39% of the control animals survived 
after 16 days. This resulted in a significantly reduced (55 - 61%) mortality in the 
immunized groups. 
- 71-
-"#. 
-
-«< 
> 
·-> 
.. 
:::t 
tn 
1 0 0 .------.,.,.....-....... 
""' 
' ,, 
\ \ \ \ 80 
' \ \ \ \ 
. \ ... \ \........ ', 60 
\ 
.... 
. \ ' \ \ ' 
. \ ' 40 
• 
\ '........ '\.-...... . \ -- .... , .... --
......... ______ ........ _!__ 20 
.\ 
5 7 9 11 13 15 
Days after infection 
25 mg 
12.5 mg 
6.25 mg 
controls 
Figure 1. Survival rates of study 1. Animals were infected directly after the immunization period (day 10) with 
high-dose influenza A. * p :!! 0.05, survival of immunized animals vs survival of controls, Kaplan-Meier 
product-limit survival estimates. 
Study 3. Fifteen days after infection all animals in both groups had died (figure 3). 
Survival time in the immunized group (8 - 15 days), however, was significantly longer 
than in the control group (8- 10 days). 
Study 4. Figure 4 shows survival rates of the four different groups from days 6 - 16 after 
infection. After fourteen days, no more animals died. Survival in the group immunized 
with 25 mg Paspat oral• was significantly better than in the saline treated control group 
and was comparable to the results obtained in the first survival study (study 1). In the 
groups treated with CyA, survival was also significantly better in the immunized group 
than in the saline treated control group receiving CyA However, immunosuppression 
with CyA significantly reduced the protective effect of Paspat oral•. No significant 
difference was found between the two saline treated control groups. 
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Figure 2. Survival rates of study 2. Animals were infected directly after the immunization period (day 10) with 
low-dose influenza A * p ~ 0.05, survival of immunized animals vs survival of controls, Kaplan-Meier product-
limit survival estimates. 
Study 5. Immediately after immunization (day 10), there was no difference between the 
immunized and control group with respect to thorax-lung compliance, protein 
concentrations in BAL fluid or surface tensions of BAL fluid (table 1). On the fifth day 
after infection (day 15) thorax-lung compliance was significantly decreased in the control 
group compared to day 10 and was significantly lower than in the immunized group. At 
day 15, protein concentrations in BAL fluid were significantly increased in both groups 
compared to day 10. However, concentrations remained significantly lower in the 
immunized group compared to controls indicating a more increased permeability of the 
alveolo-capillary membrane in the control group (table 1). 
Also on day 15, minimal surface tension of BAL fluid was significantly higher in the 
control group compared with immunized animals, indicating loss of surfactant in the 
control group (table 1). 
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Figure 3. Survival rates of study 3. Animals were infected two weeks after the immunization period (day 24) 
with high-dose influenza A • p !': 0.05, survival of immunized animals vs survival of controls, Kaplan-Meier 
product-limit survival estimates. 
Viability of the alveolar macrophages in BAL fluid (tested by trypan blue exclusion) 
ranged from 85-93%. Table 2 shows basal concentrations of cAMP of AMs before and 
after infection. Directly after immunization (day 10) AMs obtained from immunized 
animals showed less cellular activity, as concluded from significantly higher cAMP levels 
compared to AMs collected from control animals (table 2). Five days after infection, 
macrophageal activity in both groups had significantly increased as indicated by reduced 
cAMP concentrations in both groups. At this time, however, AMs collected from 
immunized animals showed significantly higher cellular activity than the AMs of control 
animals (table 2). 
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Table 1. Thorax lung compliance and protein concentrations in BAL fluid. 
C/kg 
(mi.cm H20"1.kg"1) 
Day 10 
0.90 
(0.24) 
Day 15 
0.89 
(0.19) 
Protein cone. in BAL 0.72 0.67 
(mgjmr1) (0.26) (0.10) 
Surface active properties of 400 JLI BAL fluid measured with a modified Wilhelmy Balance. 
Day 10 Day 15 
immunized controls immunized controls 
Area 0.21 0.18 0.28 # 0.27 # 
(mN) (0.16) (0.10) (0.08) (0.10) 
Maximal surface 58.1 55.0 65.5 # 64.7 # 
tension (mN.m"1) (5.9) (5.4) (4.0) (2.7) 
Minimal surface 22.6 22.4 23.5 * 27.1 # 
tension (mN.m-1) (4.7) (3.7) . (3.7) (4.0) 
Thorax-lung compliance, protein concentrations in BAL fluid and surface active properties of BAL fluid 
obtained from immunized and control animals, directly after the end of the immunization period (day 10) and 
five days after infection (day 15). * p ~ 0.05, concentrations in macrophages from immunized animals vs 
controls, # p ~ 0.05, day 10 vs day 15. Mann-Whitney U test. 
Incubation of AMs with PGE2 (table 2), directly after immunization, significantly reduced 
cellular activity compared to basal levels in both groups. However, on the filth day after 
infection, activity of AMs from immunized animals was significantly higher after 
incubation with PGE2 than activity of AMs from control animals. Incubation with 
histamine (table 2) also resulted in significantly reduced macrophageal activity in both 
groups, although to a lesser extent than PGE2• Directly after the immunization period 
cellular activity of AMs obtained from immunized animals was significantly more reduced 
than cellular activity of AMs from control animals. Five days after infection no difference 
could be observed between both groups. 
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Figure 4. SuiVival rates of study 4. Animals were infected directly after the immunization period (day 10) with 
high-dose influenza A * p :$ 0.05, sutvival of immunized animals vs sutvival of controls, # p :$ 0.05, sutvival 
of immunized immunosuppressed animalsvs saline treated immunosuppressed animals, Kaplan-Meierproduct-
limit survival estimates. 
DISCUSSION 
Most orally applied immunomodulators are developed empirically and consist of lysates 
of one or more different bacteria or bacterial components. Such preparations, applied 
orally, result in protection against exacerbation of chronic obstructive lung disease in 
infants [Maestroni & Losa (1984)] as well as in adults prone to frequent respiratory 
infection [Clancy, Cripps, Murree-Allen & Yeung (1985) ]. Scientific acceptance of these 
preparations, however, is limited due to poor characterization of the active components 
and poor understanding of underlying mechanisms. 
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Table 2. Macrophageal activity. 
Day 10 DaylS 
immunized controls immunized controls 
Basal conditions 0.43 * 0.40 0.16 *,# 0.19# 
(0.01) (0.01) (0.02) (0.03) 
Histamine 1,21 * 0.68 0.23# 0.26# 
(0.29) (0.15) (0.05) (0.05) 
PGE2 7.24 8.46 0.44 *,# 0.80# 
(0.93) (1.44) (0.08) (0.07) 
Concentrations (pmouo·5 cells) of cyclic-AMP (cAMP) in alveolar macrophages, obtained by bronchoalveolar 
lavage (BAL) from immunized and control animals, directly after the end of the immunization period (Day 
10) or 5 days after infection with influenza A virus (Day 15). Concentrations of cAMP were measured directly 
after BAL (basal concentrations) or after stimulation with histamine or prostaglandin E2 (PG~. * p !5 0.05, 
concentrations in macrophages from immunized animals vs controls, # p !5 0.05, day 10 vs day 15. Mann-
Whitney U test. 
Concentrations, administered in experimental and clinical studies on oral immunization, 
differ widely. The concentrations of Paspat oral• used in these studies are the same as 
those found to have a protective effect against S. pneumoniae in our previous studies on 
oral immunization [Van Daal, et al. (1990a); Van Daal, et al. (1990b)]. These high 
concentrations, also empirically found, are without adverse side effects as evidenced by 
a similar gain in bodyweight during the immunization period in both immunized and 
control groups (data not shown). Furthermore, immunization itself did not influence 
thorax-lung compliance, protein concentrations or surfactant activity in BAL fluid. 
The dosages and time schedules used in these studies may not be directly applicable to 
the clinical situation. We do presume, however, that the presented results may help to 
further clarify the underlying principles of oral immunization. 
The relative contribution of different immune mechanisms to resistance to infection is 
difficult to identify. It is, however, reasonable to suggest that both mucosal and systemic 
immune responses [Murphy & Clements (1989)] participate in this resistance. During the 
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first few days of influenza infection in nonimmunized hosts, the virus must inhibit or 
avoid nonspecific, cell-mediated defense mechanisms on, within, and below the surface 
epithelium of the respiratory tract [Sweet & Smith (1980)]. Therefore, in this study we 
wanted to investigate whether these cell-mediated mucosal defense mechanisms can be 
sufficiently enhanced, by oral immunization with a bacterial lysate, to protect mice 
against infection with influenza A 
It was found that oral immunization with Paspat oral• can reduce mortality due to 
influenza A infection with 15-70%, depending on the quantity of virus administered. 
Furthermore, protection by oral immunization seems to be dose-dependent, at least with 
a high virus dose. With a low virus dose, the protective effect of the lysate does not seem 
to be dose-dependent but lower concentrations of the lysate might have resulted in 
similar dose-dependent protection. Although in the groups infected two weeks after 
immunization (study 3) a significant increase was found in the immunized group with 
regards to survival time, oral immunization did not result in a reduced mortality at the 
end of the study, 20 days after infection. These fmdings suggest an important role for 
cell-mediated defense in the protective mechanisms stimulated by oral immunization with 
a bacterial lysate. It is improbable that specific antibody formation against influenza plays 
a major role in our experiments, considering the time schedule we applied in this study. 
Mice used in this study had not previously encountered influenza antigens and cross-
reactivity of the bacterial lysate with influenza hemaglutinin antigens seems unlikely too, 
because we could not demonstrate hemaglutinating activity in BAL fluid of mice orally 
immunized with Paspat oral'" (unpublished observations). In addition, the protective 
effect of oral immunization, as achieved in this study, almost entirely disappeared within 
two weeks and we opine that the protective effect must be looked for in nonspecific 
mechanisms, such as activation of cytotoxic or phagocytotic cells. 
In several animal models, injection of a nonspecific immunomodulator, muramyl 
dipeptide (MDP), resulted in resistance against bacterial, viral and fungal infections. The 
involved mechanisms are thought to include interferon production [Sakuma, Suenaga, 
Yoshida & Azuma (1983)] activation of macrophages and amplification of numerous 
immune responses by release oflymphokines from macrophages [Chedid, Parant, Parant, 
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Lefrancier, Choay & Lederer (1977); Cummings, Pabst & Johnson (1980); Wyde, Six, 
Ambrose & Throop (1990)]. We therefore chose to suppress T-cell function with CyA 
to investigate the importance of T -cells in the protective effect of oral immunization in 
mice infected with influenza A. Cytotoxic T cells play an important role in the clearing 
of influenza virus [Ennis, Hua & Schild (1982)] and protect the infected host by 
recognizing and killing virus-infected target cells [Taylor & Askonas (1986)]. CyA 
completely blocks anti-influenza A cytotoxic T -cells [Amerding (1981) ], reduces primary 
and secondary response of Theiper-ce1ls [Hess, Tutschka & Santos (1982)] and thereby 
IFN-gamma production [Kalman & Klimpel (1983); Reem, Cook & Vilcek (1983)] 
whereas T-cell mediated suppression is not altered [Hess, Tutschka & Santos (1981); 
Leapman, Filo, Smith & Smith (1980)]. 
CyA severely reduced the protective effect that could be achieved by oral immunization 
in our survival studies, which implies that a major effect of oral immunization in these 
studies is T-cell activation and increased IFN-gamma production as described earlier 
[own observations (submitted); Emmerich, et al. (1990a); Emmerich, et al. (1990b)]. Oral 
immunization enhances NK cell cytotoxicity both in vitro and in vivo [Normier, Pniel, 
Dussourd D'Hinterland, Ramstedt & Wigzell (1985)], it might therefore be that 
enhanced activity of NK cells is responsible for part of thy observed protective effect 
against influenza A infection in this study. Reduced IFN-gamma production by CyA 
results in reduced natural killer (NK) cell activity [Gui, Ho & Camp (1982)]. However, 
is has also been observed that NK activity after CyA immunosuppression in influenza 
infected mice was comparable to control levels. This state of tolerance for CyA was 
specific for influenza virus infection [Schiltknecht & Ada (1985)]. 
Numbers of AMs increase during the cellular response to influenza infection in humans 
and mice [Raut, Hurd, Cureton, Blandford & Heath (1975)]. IFN-gamma primes 
macrophages to react more violently to stimulation. Suppression ofT-helper cells with 
CyA will result in decreased production of IFN-gamma [Kalman & Klimpel (1983)] and 
may thereby decrease macrophageal activity, although other authors found that activity 
of guinea pig peritoneal macrophages was not influenced by CyA [Thomson, Moon, 
Geczy & Nelson (1983)]. It is conceivable that, in this study, macrophages were already 
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activated to a cytotoxic state by oral immunization, before the application of CyA was 
started (one day before infection) and could therefore react more strongly to virus 
infection than control macrophages, which might also explain the observed difference in 
survival between immunized animals receiving CyA and control animals receiving CyA. 
In patients with chronic bronchitis, oral immunization enhanced metabolism of alveolar 
macrophages [Munteanu, SchOtler, Milatovic, Emslander, Daum & Emmerich (1986)]. 
Other authors described increased activity of murine peritoneal macrophages after 
stimulation in vitro with oral immunomodulators [Normier, et al. (1985); Vacheron, 
Perin, Kodari, Smets, Zalisz & Guenounou (1989)]. Our findings extend these 
observations to AMs of orally immunized animals after infection with influenza A 
Before infection basal activity levels of AMs in immunized mice were significantly lower 
than in control animals. However, five days after infection basal activity level of the AMs 
in immunized mice was significantly higher than AM activity in controls. Inflammatory 
pulmonary processes induce release of arachidonic acid metabolites [Peters, McGlashan, 
Schleimer, Hayes, Adkinson & Lichtenstein (1985); Rankin, Hitchkock, Merrill, Bach, 
Brashier & Ashkenase (1982)]. These metabolites (like PGE2) stimulate adenylate cyclase 
and thereby increase intracellular cAMP concentrations, reflecting decreased cellular 
activity and decreased phagocytotic capacity [Adolfs & Bonta (1982); Ashby (1986)]. 
Stimulation of AMs with PGE2 significantly reduced cellular activity in both groups, 
before and after infection. However, cellular activity of AMs from immunized animals 
was less reduced than cellular activity of control macrophages. This fmding might 
indicate that AMs from orally immunized animals are less sensitive to the inactivating 
properties of arachidonic acid metabolites like PGE2 and may, therefore, better maintain 
phagocytotic capacity than control macrophages. 
Cellular activity of AMs of immunized animals was significantly more reduced by 
histamine than activity of control macrophages. These observations might indicate that 
cellular activity of AMs in orally immunized individuals might be reduced after histamine 
release during anaphylactoid reactions. This might prove especially important in 
asthmatics when the secretory functions of AMs are considered. Amongst a variety of 
other mediators, AMs secrete potent proinflammatory mediators [Henderson (1987)] like 
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thromboxane A2, a constrictor of pulmonary vessels [Samuelsson, Goldyne, Granstrom, 
Hamberg, Hammarstrom & Malmsten (1978)], and leukotriene B4, a potent 
chemoattractant for eosinophils [Goetzl, Pickett (1981)] which increases pulmonary vessel 
permeability [Dahlen, Bjork, Hedqvist, Arfors, Hammarstrom, Lindgren & Samuelsson 
(1981)] and constricts pulmonary airways [Whittle & Moncada (1983)]. 
Therefore, oral immunization might prove to be an interesting method to modulate 
cellular reactivity to allergenic stimuli, and further investigations in this direction seem 
necessary. 
Summarizing, we conclude that oral immunization with Paspat oral• stimulates T cell 
dependent immune mechanisms, resulting in efficient protection against influenza A virus 
infection in mice. The survival rate of orally immunized mice infected with influenza A 
virus seems to be dependent on: lysate concentrations applied, inoculum dose, and time 
between the moment of infection and the end of the immunization period. Furthermore, 
AMs appear to play an active role in protection against influenza A infection resulting 
from oral immunization with Paspat oral•. 
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CHAPTER VI 
INTRODUCTION TO PULMONARY SURFACTANT 
In the adult lung, alveoli are coated with a film of surfactant consisting mainly of 
phospholipids and surfactant -associated proteins. Surfactant "floats" on the hypophase 
like a soap-molecule and reduces the surface tension at the air-liquid interface of the 
alveolus which prevents the airspaces from collapsing at end-expiration [Clements '77, 
King '82]. Surfactant is produced by, stored in and excreted from the type II pneumocytes 
[Goerke '74, King '82]. The major intracellular pool of surfactant is found in the form 
of "lamellar bodies" in the type II cells [Chevalier '72]. When lamellar bodies are 
excreted by exocytosis they transform into so-called tubular myelin [Wright '87], an 
intermediate structure from which the surfactant spreads to the air-liquid interface of the 
alveolus to form the active film [Hallman '81]. Clearance of surfactant from the alveolar 
space occurs mostly by reuptake and reutilization of the surfactant lipids by the type II 
cells [Jacobs '83]. 
Composition of surfactant 
Extracellular surfactant, obtained from dogs by bronchoalveolar lavage, consists of 8% 
protein, 90% lipid and about 2% carbohydrate [King '72]. Over 85% of surfactant lipids 
is phospholipid; phosphatidylcholine (PC), of which generally over 60% is disaturated 
(DPPC), makes up 70-85% of the phospholipid fraction. The remainder consists of other 
phospholipids of which phosphatidylglycerol ( ± 10% of total phospholipid fraction) 
makes up the largest fraction [King '84]. Relatively little interspecies difference is found 
with respect to the phospholipid fraction of pulmonary surfactant [King '84]. Without the 
presence of specific surfactant-associated proteins DPPC, which is the major surface 
tension reducing component of surfactant, does not adsorb and spread at a sufficient rate 
to the surface of the air-liquid interface to support normal lung function [Goerke '74, 
Notter '84, Van Golde '88]. At least four surfactant-associated proteins (Sp-A, B, C and 
D) are produced by type II cells [Dobbs '82, Wartell '83, Weaver '89, Liley '88, Persson 
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'89] which have, apart from functions such as the regulation of phospholipid metabolism, 
an important function in the formation of the surfactant monolayer [King '86, Possmayer 
'90]. 
Functions of surfactant 
The primary functions of surfactant are stabilization of alveoli of different size, and 
reduction of the work of breathing by reducing surface tension [Clements '77]. Without 
the presence of a functional surfactant layer, small alveoli will empty into larger ones 
according to Laplace's law (P = 2I' jr; P = pressure in the alveolus, r = surface tension 
at the air-liquid interface, r = radius of the alveolus). Surfactant changes the net surface 
tension in a manner related to the actual size of the alveoli. With decreasing size of the 
alveolus the surfactant film is concentrated and certain components are "squeezed out" 
into the hypophase until, at the end of maximal expiration, a densely-packed lining of 
phospholipids remains which exerts a pressure gradient that counteracts the surface 
tension of the alveolar walls with the hypophase. By the same mechanism, surfactant is 
partly responsible for maintaining functional residual capacity [Goerke '74, Clements '77]. 
Furthermore, surfactant functions as an anti-edema factor, by stabilizing the fluid balance 
of the lungs [Guyton '84]. Alveolar flooding will not occur as long as the suction force 
in the pulmonary interstitium exceeds the pressure gradient (which is dependent on the 
size of the alveolus) generated by the surface tension in the alveolar liquid interface. 
Other functions of the surfactant system comprise involvemelx in pulmonary defense 
mechanisms [Huber '76, J arstrand '84, Coonrod '86, van Iwaarden '90], non-ciliary and 
mucous clearance of particles from the airways [Green '73] and protection of the 
cardiocirculatory system against inhaled pharmacologically active substances [Smit '87]. 
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Consequences of surfactant deficiency 
Functional impairment of the surfactant system has far-reaching consequences for the 
functioning of the lung. Independent of the cause, decreased surfactant function will 
directly or indirectly lead to [Lachmann '84]: 
decreased pulmonary compliance 
decreased functional residual capacity of the lung 
atelectasis 
pulmonary edema with decreased gas exchange and respiratory acidosis 
hypoxemia with anaerobic metabolism and metabolic acidosis 
further inactivation of surfactant by plasma constituents 
enlargement of the functional right-to-left shunt of the lung 
However, in some cases it is difficult, if not impossible, to prove that a surfactant 
deficiency is the cause for decreased lung function or presenting clinical symptoms. 
Surfactant replacement therapy 
Based on the above mentioned, a simple but rational philosophy was developed to 
manage the problems caused by surfactant deficiency [from Lachmann '88]: 
1 If surfactant is necessary for keeping retractive forces as low as possible and for 
optimal gas exchange, any disturbance in the surfactant system will result in 
abnormalities in lung distensibility and gas exchange. 
2 If 1 is correct, surfactant replacement will restore lung distensibility and gas 
exchange to normal. 
Idiopathic respiratory distress syndrome (IRDS) 
It has been established that IRDS /hyaline membrane disease results from prematurity 
of the newborn and its surfactant system [Avery '59]. Surfactant replacement therapy, 
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with different preparations, has been used with considerable clinical benefits in several 
studies on the treatment of IRDS [Fujiwara '80, Hallman '85, Gitlin '87] and in studies 
on the prevention of IRDS [Enhorning '85, Kwong '85, Shapiro '85, Merritt '86, Morley 
'87]. Although the beneficial effects of surfactant replacement therapy have not always 
been consistent [Avery '86], the overall effects comprise reduced mortality of IRDS and 
reduced morbidity of IRDS including reduced bronchopulmonary dysplasia. 
Adult respiratory distress syndrome (ARDS) and ARDS-like lung diseases 
Ashbaugh and coworkers introduced the concept of ARDS [Ashbaugh '67],which 
comprises respiratory failure resulting from sepsis, polytrauma, liquid aspiration, multiple 
organ failure, burns, pneumonia and many other diseases [Hopewell '77]. An operational 
definition of ARDS comprises the following features: an appropriate risk factor, severe 
hypoxemia refractory to increased inspiratory oxygen concentrations (Pa02/FP2 < 150 
mm Hg), decreased lung compliance, bilateral diffuse infiltration on the chest X-ray and 
severe pulmonary edema. In studies on the development of ARDS and in studies on 
established ARDS, compositional changes in surfactant and decreased surfactant content 
of the lungs were observed [Ashbaugh '67, Lachmann '77, Von Wichert '77, Petty '79, 
Hallman '82, Lachmann '84, Seeger '90]. Furthermore, biochemical abnormalities of lung 
surfactant in ARDS patients were present early in respiratory failure but tended to 
normalize during recovery [Hallman '82]. 
First clinical trials [Lachmann '87, Richman '89] and experimental studies [for review see 
Holm '89] showed that surfactant replacement therapy can restore lung function in 
ARDS of different etiology. Therefore, surfactant replacement therapy seems a promising 
approach for the treatment of acute respiratory failure in ARDS and ARDS-like 
syndromes. 
To date, surfactant replacement therapy has been studied in only a limited number of 
ARDS-patients, whereas well over 15,000 babies suffering from IRDS have been treated 
with surfactant. The non-homogeneity of ARDS patients dictates further investigations 
to evaluate the efficacy of surfactant replacement therapy in animal models and patients 
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with ARDS from different etiology. Therefore, the usefulness of surfactant replacement 
therapy in ARDS-like respiratory failure caused by viral pneumonia is evaluated in the 
following chapters. 
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CHAPTER VII 
ACUTE RESPIRATORYFAILURE DURING PNEUMONIA INDUCED 
BY SENDAI VIRUS 
SUMMARY 
In this study a model of acute respiratory failure due to viral pneumonia in rats, closely 
resembling ARDS, is presented. Severe respiratory failure with lethal outcome in four 
days was induced by infection concentrated Sendai virus aerosol. This model permits 
evaluation of different therapeutical approaches for improving gas exchange during 
ARDS. Furthermore, preliminary results of surfactant substitution therapy in this model 
are presented. 
INTRODUCTION 
Although there is no universal agreement on the criteria for the diagnosis of the adult 
respiratory distress syndrome (ARDS), the syndrome is characterized by distinct clinical 
and pathophysiological features (Ashbaugh et' al., 1967; Petty and Ashbaugh 1971). 
ARDS can be the outcome of a number of disorders including shock of any etiology, 
infectious causes, trauma, drug overdose and many others (Hopewell and Murray, 1977). 
During the past 20 years little has changed in the possibilities for the treatment of ARDS 
and the mortality rate is still extremely high (50 - 70%) (Shale, 1987). 
In this study a model of acute respiratory failure due to viral pneumonia in rats, closely 
resembling ARDS, is presented. This model permits evaluation of different therapeutical 
approaches for improving gas exchange during ARDS. Furthermore, preliminary results 
of surfactant substitution therapy in this model are presented. 
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MATERIALS AND METHODS 
Animals 
Male Sprague-Dawley rats (n=32, SPF, 170-200 g) were used. Rats were housed under 
filter bonnets and autoclaved food and water were available ad libitum. Infected animals 
were removed and kept separately in another facility. Twenty-four non-anesthetized 
animals were randomly assigned to four groups and were exposed for 90 min in an 11 
liter aerosol chamber, through which an aerosol (1: 2 dilution in PBS of stock solution) 
flow of 5 ljmin was led. Aerosol was produced with an air jet nebulizer (Ultravent, 
Malinckrodt Diagnostica, The Netherlands). This device produces small particles, size 
0.6 - 2 J..I.ID (Dahlbiick et al., 1986), which allows for alveolar deposition of the aerosol 
(Brain and Valberg 1979). Two animals were infected in the same way for histological 
examination of the lungs. Six additional animals served as healthy controls. 
Virus 
Sendai virus (Myxovirus parainfluenza type 1) is a single-stranded RNA virus (150-200 
nm diameter) belonging to the family of the paramyxoviruses, to which several important 
human viruses also belong (e.g. mumps, measles and respiratory syncytial virus). Sendai 
virus generally replicates in respiratory epithelium (Ito et al., 1982; Ito et al., 1983; 
Tyrrell and Coid, 1970), primarily in bronchial and bronchiolar epithelium (Blandford 
and Heath, 1972). Sendai virus was propagated in 11-day embryonated chicken eggs. The 
hemagglutination (HA) titre of the stock solution was determined to be approximately 
1:3000. 
Evaluation of arterial blood gases and surfactant substitution 
Each day one group of 6 animals was anesthetized (pentobarbital sodium 60 mg/kg i.p.), 
tracheotomized and a metal cannula was inserted into the trachea. A catheter (0.8 rom 
outer diameter) was inserted into the right carotid artery for drawing arterial blood 
samples. Animals were paralyzed (pancuronium 0.1 mg/kg i.m.) and mechanically 
ventilated with a Siemens 900c ventilator, in a pressure controlled mode, at a rate of 
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35 /min, P peak = 15 em H20 (15 /0), 1/E ratio 1:2 and Fi02 = 1. Then peak-airway pressure 
was increased to 20 em H20 (20/0). Next, peak-airway pressure was increased to 25 em 
H20 and positive-end-expiratory-pressure (PEEP) of 4 em Hp (25/4) was introduced. 
At each different ventilator setting 15 min was allowed for stabilization before 0.3 ml 
blood was collected and arterial blood gases were determined (ABL 330, Radiometer, 
Copenhagen, Denmark). On the second day after infection, two animals received 1.5 ml 
exogenous natural, bovine surfactant (phospolipids 50 mg/ml) intratracheally and were 
monitored for two hours after surfactant substitution; airway pressures 25/4, rate 35/min, 
1/E ratio 1:2 and Fi02 =1. 
Thorax-lung compliance registration 
After evaluation of the influence of different ventilator settings on blood gases, animals 
were transferred to a body-plethysmograph (for details see Lachmann et al., 1980) and 
thorax-lung compliance was registered at a rate of 6/min, P peak = 15 em H20, 1/E ratio 
1:2 and Fi02= 1. 
Statistical evaluation of data 
Data are presented as mean ± standard deviation (SD). Statistical analysis of data was 
done with the Wilcoxon test for within-group comparison and with the Mann-Whitney 
U test for between-group comparison. Statistical significance was accepted at p ~ 0.05 
(two-tailed). 
RESULTS 
Bodyweight of infected animals (182.8 ± 35.3 g, day 3 and day 4 group, n=12) increased 
during the first day after infection (202.1 ± 52.3 g); animals suffered significant 
weightloss during the second (197.3 ± 51.3 g) and the third day (173.0 ± 44.8 g) after 
infection. Furthermore, animals showed clinical signs of illness like ruffled fur, tachypnea, 
rhinitis and reduced motility from the first day after infection. Figure 1 shows mean 
arterial oxygen (Pa02) and carbon dioxide (PaC02) tension of control animals and three 
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groups of infected animals, on three successive days after infection, during artificial 
ventilation (P peak = 15 em HzO, I/E ratio 1:2 and Fi02 = 1). With these ventilator 
settings Pa02 dramatically decreased from the first day after infection whereas PaC02 
significantly increased. 
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Figure 1. Mean arterial oxygen (Pa02J and carbon dioxide (PaCOz) tension of control animals and three 
groups of rats, infected with Sendai virus, on three successive days after infection, during artificial ventilation 
(P peak = 15 em HzO, I/E ratio 1:2 and Fi02 = 1). * p:; 0.05, vs controls, n=6/group. 
Arterial pH (Table 1) was significantly decreased in all groups of infected animals 
whereas arterial bicarbonate concentration (HC03-) was not significantly different 
compared to controls. The remaining six animals (day 4 group) died spontaneously 
between the third and the fourth day after infection and blood gases and thorax-lung 
compliance could, therefore, not be evaluated. 
Thorax-lung compliance was significantly decreased on the second and the third day after 
infection (Fig. 2) whereas protein concentrations of bronchoalveolar lavage (BAL) fluids 
were significantly increased on all three days after infection (Fig. 2). 
The effect of increased peak airway pressures on Pa02 is shown in figure 3. Only on the 
second day after infection P peak of 25 em H20 with PEEP of 4 em H20 significantly 
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Table 1. 
PaC02 pH HC03" 
(mmHg) (mmol/1) 
15/0 20/0 25/4 15/0 20/0 25/4 15/0 20/0 25/4 
contr. 32.7 7.49 24.4 
(5.6) (0.03) (2.6) 
day 1 45.7# 36.1* 38.6* 7.31# 7.40* 7.36* 22.6 21.6 21.3 
(3.9) (3.7) (3.0) (0.02) (0.03) (0.03) (1.3) (1.1) (1.2) 
day 2 44.3# 43.9 38.3 7.32# 7.32 7.35 215 21.5 19.9 
(10.8) (10.4) (8.1) (0.1) (0.09) (0.07) (1.0) (1.5) (15) 
day3 56.8# 54.9 57.6 7.29# 7.30 7.29 26.3 25.8 26.7 
(12.3) (12.6) (14.0) (0.07) (0.08) (0.08) (2.0) (1.9) (1.7) 
Influence of different ventilator settings on arterial PC02, pH and HCo3·, during the course of infection in 
rats infected with Sendai virus. Animals were mechanically ventilated with a Siemens 900c ventilator, pressure 
controlled, at different pressures at a rate of 35/min, I/E ratio 1:2 and Fi02= 1. Data are presented as mean 
(SD), n=6 per group. # p :S 0.05, MW U-test, infected animals vs controls. • p :S 0.05, Wilcoxon test, vs 
controls. 
increased Pa02• Increased airway pressures did not result in significantly increased Pa02 
on days one and three after infection. However, increased airway pressures significantly 
reduced PaC02 and increased pH on the first day after infection whereas levels of 
significance were not reached on days two and three (Table 1). Increased airway 
pressures did not significantly influence HC03- (Table 1). 
The increase of airway pressures from 15/0 to 25/4 only slightly increased Pa02, whereas 
instillation of surfactant restored Pa02 almost to normal (Fig. 4). 
Histological examination of lungs of two infected animals two days after infection showed 
alveolar flooding with protein rich fluid and atelectatic areas. 
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Figure 2. Thorax-lung compliance (C/kg) and protein content (mg/ml) of BAL fluid of rats infected with 
Sendai virus. * p :S 0.05, vs controls, n=6jgroup. 
DISCUSSION 
We wanted to investigate whether we could induce severe respiratory failure in rats by 
infection with Sendai virus. Studies of intranasal inoculation of rats with high dose Sendai 
virus, as described by Giddens et al. (Giddens et al., 1987), performed earlier in our 
laboratories, did not result in hypoxemia or acidosis. This in spite of the fact that animals 
showed clinical signs of illness like ruffled fur, rhinitis, reduced motility and loss of 
bodyweight. However, animals spontaneously recovered within one week after infection. 
Therefore, we decided to employ concentrated live Sendai virus aerosol during an 
extended period of time. In this way we were able to induce severe respiratory failure 
with lethal outcome in four days. During the progression of the infection animals 
suffered significant loss of bodyweight and showed severe signs of illness. 
At ventilator settings which resulted in hyperventilation and respiratory alkalosis in 
control animals, infected animals showed hypoventilation and respiratory acidosis as a 
result of mismatching between ventilation and perfusion of the lungs; PaC02 of infected 
animals increased to 135% (day 2) and 173% (day 3) of PaC02 of control animals. 
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Figure 3. Effect of increased airway pressures on arterial oxygen tension (P a O:z) during artificial ventilation 
of rats infected with Sendai virus. • p :S 0.05, vs 15/0, n=6/group. 
Furthermore, infected animals developed severe hypoxemia as a result of atelectasis, 
flooded alveoli and, as mentioned above, mismatching between ventilation and perfusion; 
Pa02 of infected animals decreased to 31% (day 2) and 35% (day 3) of Pa02 of control 
animals in three days. 
An intact surfactant system is indispensable for the maintenance of proper lung function 
and therefore any type of surfactant deficiency, whether primary or secondary, will 
contribute to the development of severe pulmonary pathology. 
It appears that loss of surfactant function is not the primary pathogenic factor for the 
occurrence of the severe respiratory failure in this study, but it may contribute 
significantly. 
Infection with Sendai virus may lead to destruction of type I cells and loss of integrity 
of the alveolar-capillary membrane, allowing albumin and other macromolecules to enter 
the alveoli, as observed in this study. One of the common characteristics of ARDS is the 
accumulation of protein-rich edema in the alveolar space (Hopewell and Murray, 1977; 
Rinaldo and Rogers, 1982; Shale, 1987; Bradley, 1987). 
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Figure 4. Effect of increased airway pressures and surfactant instillation on arterial oxygenation during 
artificial ventilation of 2 rats infected with Sendai virus. 
Edema components like plasma proteins and cell membrane constituents inhibit the 
biophysical activity of the surfactant system (Holm et al., 1985; Holm and Notter, 1987; 
Ikegami et al., 1984; Fuchimukai et al., 1987; Seeger et al., 1985). Furthermore, 
destruction of type II cells may decrease surfactant synthesis and secretion. 
Increasing ventilatory pressures to 20/0 did not significantly increase P.02• Only P peak = 
25 em H20 with PEEP (4 em H 20) could significantly increase P.02 of infected animals 
(92% increase) on day 2, which is evidence for a surfactant deficiency. Any tendency for 
alveolar collapse during endexpiration - which can be compensated only by 
counterpressure e.g. PEEP- speaks for a surfactant deficiency in these areas. To prove 
this, we performed surfactant replacement in two animals with severely reduced arterial 
oxygenation. Surfactant substitution restored arterial oxygenation to normal whereas 
increased airway pressures (25 / 4) alone did not; this indicates that surfactant deficiency 
is one of the major pathogenic causes of respiratory failure in this model of ARDS. 
However, since the applied ventilator settings were not very effective in restoring gas 
exchange, higher pressures or different modes of ventilation might have improved arterial 
oxygenation and reduced acidosis in infected animals. 
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Although there is no overall consensus on the criteria for the diagnosis of ARDS, the 
essential features of ARDS are met in this animal model (Pepe et al., 1982; Fowler et 
al., 1983; Stevens and Raffin, 1984). Infection of rats with Sendai virus led to acute 
respiratory failure with severe hypoxemia, increased intrapulmonary shunting, stiff lungs 
and pulmonary edema. 
Surfactant replacement therapy seems to be a promising approach for the treatment of 
ARDS-like syndromes caused by viral pneumonia, as can be concluded from the 
preliminary results following surfactant replacement in this study. Several animal models 
of ARDS have demonstrated some form of surfactant deficiency or dysfunction and in 
seven of these models the beneficial effects of exogenous surfactant has been 
demonstrated: pulmonary oxygen toxicity (Holm et al., 1985), pulmonary damage induced 
by xanthine oxidase instillation (Saugstadt et al., 1984), in vivo lung lavage (Lachmann 
et al., 1980), bilateral cervical vagotomy (Berry et al., 1986), anti-lung serum infusion 
(Lachmann et al., 1987), induced damage to bronchial surfactant by artificial ventilation 
combined with saline instillation (Lachmann, 1985), and finally influenza A virus 
pneumonia in mice (Lachmann and Danzmann, 1984). 
Although most of these models show characteristic features of ARDS, inevitable 
variations exist concerning the technique employed for the induction of pulmonary 
damage. Therefore, we opine that this virus model m~y help clarify the underlying 
principles of ARDS and from the various therapeutic approaches available elucidate 
which approach is most appropriate. 
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CHAPTER EIGHT 
INTRATRACHEAL SURFACTANT ADMINISTRATION RESTORES 
GAS EXCHANGE IN EXPERIMENTAL ARDS ASSOCIATED WITH 
VIRAL PNEUMONIA 
SUMMARY 
The effect of intratracheal surfactant administration was studied in rats with adult 
respiratory distress syndrome (ARDS) associated with infection with nebulized Sendai 
virus. Thirty-six hours after infection animals (n=7) showed severely impaired gas 
exchange and acidosis during artificial ventilation (Pa02 = 152.2 ± 18.7, PaC02 = 65.3 
± 19.2, pH = 7.26 ± 0.11) with a pressure- controlled mode, standard frequency 35 /min, 
Ppeak = 15 em Hp (15/0), I/E ratio = 1:2 and F;02 = 1. Gas exchange improved 
(p=0.02) with increased ventilator pressures with PEEP (25/4). Fourty-eight hours after 
infection blood gas tensions could no longer be significantly improved by these same 
ventilator settings (Pa02 = 123.8 ± 31.0, PaC02 = 95.1 ± 43.6, pH = 7.12 ± 0.16, n=9). 
At this time, surfactant replacement dramatically incre,ased arterial oxygenation within 
five minutes (Pa02 = 389.4 ± 79.9) and resulted in a fourfold increase in Pa02 within two 
hours. It is concluded that intratracheal surfactant administration is a promising approach 
in the treatment of respiratory failure during ARDS associated with viral pneumonia. 
INTRODUCTION 
First conceptualized in the late Sixties (1), the adult respiratory distress syndrome 
(ARDS) is now recognized as the result of lung damage from a number of causes (2), 
including sepsis, polytrauma, aspiration, multiple organ failure, burns, pneumonia and 
many other conditions (3). Although there is no agreement on criteria for the diagnosis 
of ARDS, an operational definition of ARDS includes at least the following features: an 
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appropriate risk factor; severe hypoxemia refractory to increased inspiratory oxygen 
concentrations (Pa02/FP2 < 150 mmHg); decreased lung compliance; bilateral diffuse 
infiltration on the chest radiograph and severe pulmonary edema. Presently, despite 
increased sophistication in methods of respiratory support, mortality associated with 
ARDS is still around 50 - 70%, whatever the criteria of diagnosis ( 4-6). 
Development of respiratory failure in ARDS patients is highly correlated with surfactant 
abnormalities and the progressive time course suggests that compositional changes of 
alveolar phospholipid in ARDS reflect type II cell injury in the course of posttraumatic 
pulmonary insufficiency (7, 8). Furthermore, decreases in surfactant content are found 
in lung specimens from ARDS patients and abnormalities in lung elastic properties and 
increased surface tension of alveolar surfactant are present in postmortem 
bronchoalveolar lavage fluid (1, 9, 10, 11). 
Clinical trials (12, 13) and data from experimental studies indicate that exogenous 
surfactant therapy can restore lung function in ARDS of different etiology (for reviews 
see 14 and 15). Therefore, although surfactant deficiency does not appear to be the 
primary pathogenic factor in ARDS, surfactant substitution may be a promising approach 
in the treatment of ARDS (12, 13). 
Because ARDS is often associated with pneumonia of different etiology, experimental 
models are required to investigate surfactant replacement therapy in this type of 
respiratory failure. There are indications that surfactant deficiency plays a role in the 
development of respiratory failure due to viral pulmonary infection (16, 17). These 
findings are supported by data obtained from mice with influenza A pneumonia which 
demonstrate positive therapeutic effects of surfactant replacement on lung mechanics 
(18). No other information is available, to our knowledge, concerning the therapeutic 
effects of surfactant substitution during respiratory failure due to viral pneumonia. 
Therefore, we recently developed a rat model of acute respiratory failure, closely 
resembling ARDS, caused by infection with Sendai virus (19). 
We report the effects of exogenous surfactant therapy and artificial ventilation at 
different ventilator pressures on arterial blood gas tensions during respiratory failure. 
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MATERIALS AND METHODS 
Male Sprague-Dawley rats (n=41, 180-200 g, SPF) housed under filter bonnets, with 
autoclaved food and water available ad libitum, were used. Approval was obtained from 
the institutional animal investigation committee. Infected animals were removed and kept 
in a separate facility under identical conditions. Sendai virus (Myxovirus parainfluenza 
type 1) was propagated in 11-day embryonated chicken eggs. The thus prepared stock 
solution had a hemagglutination (HA) titre of approximately 1:3000. 
For inoculation, non-anesthetized animals were exposed for 90 min m an aerosol 
chamber, through which an aerosol (1:2 dilution of stock solution) with a flow of 51/min 
was led. Aerosol was produced with an air jet nebulizer (Ultravent, Malinckrodt 
Diagnostica, The Netherlands). This device produces small particles, 0.6 - 2 IJ.m in 
diameter (20), which allows for alveolar deposition of the aerosol (21). 
For measurement of arterial blood gas tensions, animals were anesthetized (pentobarbital 
60 mg/kg i.p.), tracheotomized and a metal cannula was inserted into the trachea. A 
catheter (0.8 mm outer diameter) was inserted into the right carotid artery for drawing 
arterial blood samples. Animals were paralyzed (pancuronium bromide 0.1 mg/kg i.m.) 
and mechanically ventilated (Siemens Servo Ventilator 900C, Siemens Elema, Sweden) 
in a pressure controlled mode, standard frequency 35/min, peak-airway pressure (P pe.J 
of 15 em H20 (15/0), inspiratory/expiratory ratio (1/E ratio) of 1:2 and 100% oxygen 
(F;02 = 1). These ventilator settings result in slight hyperventilation with moderate 
respiratory alkalosis in healthy Sprague-Dawley rats (19). 
To assess the severity of respiratory failure blood gas tensions were also measured at 
higher ventilatory airway pressures at different times after infection. P peak was first 
increased to 20 em H20 (20/0), then to 25 em H20 with a positive end-expiratory 
pressure (PEEP) of 4 em H20 (25/4). At each ventilator setting 15 min was allowed for 
stabilization before a 0.3 ml arterial blood sample was collected for measurement of 
blood gas tensions (ABL 330, Radiometer, Copenhagen, Denmark). 
Treatment with surfactant or saline (decided by prior randomization) was performed only 
in animals with arterial oxygen tension (Pa02) below 150 mm Hg ventilated at 15/0 and 
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in which increased ventilatory airway pressures (25/4) did not increase Pa02 above 175 
mmHg. 
The effect of surfactant substitution with a natural bovine surfactant, extracted in 
basically the same way as described by others (22), was evaluated 48 h after infection; 
22 animals met the preset criteria for treatment. After randomization, 9 animals were 
treated with 1.5 ml surfactant (200 mg phospholipids/kg bodyweight) intratracheally, 
whereas 7 control animals received 1.5 ml saline intratracheally and 6 other control 
animals received no treatment whatsoever except for continuation of the same ventilatory 
support that was used in the treated animals (25/4). After treatment, ventilator settings 
remained unchanged and blood gas tensions were monitored for 2 h afterwards. 
After the experiment, the chest of each animal was opened and a cannula inserted into 
the pulmonary artery. The lungs were inflated with a pressure of 20 em H20 and 
maintained at this pressure while being perfused with formalin ( 4%) through the 
pulmonary artery. After perfusion, the lungs were removed and kept in formalin (10%) 
for at least 48 h. Paraffm sections from the right middle lobe were then stained with 
hematoxylin and eosin and examined microscopically. 
All variables were analyzed by the Marm-Whitney U test for between-group comparisons 
or the Wilcoxon signed rank test for within-group comparisons. All tests of statistical 
significance were two-tailed and data were tested at the 0.05 significance level. All data 
are presented as mean ± standard deviation. 
RESULTS 
At 36 h after infection (table 1), during artificial ventilation (15/0), animals already 
showed severe signs of respiratory insufficiency with reduced Pa02, increased arterial 
carbon dioxide tension (PaC02) and acidosis. Increasing the ventilatory airway pressures 
to 20/0 did not significantly change arterial blood gases; further increase of peak airway 
pressure and introduction of PEEP (25/4), however, almost completely restored arterial 
blood gas tensions to normal values. 
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Table 1. 
15/0 20/0 25/4 
pOz 152.2 162.1 4565 * 
(mmHg) (18.7) (50.7) (65.6) 
pC02 65.3 605 46.8 
(mmHg) (19.2) (14.3) (8.2) 
pH 7.26 7.27 7.35 
(0.11) (0.08) (0.08) 
Blood gas tensions and acid-base status, mean (SD), of seven animals after infection with a lethal dose of 
Sendai virus, during artificial ventilation. Animals were mechanically ventilated with a Siemens 900c ventilator, 
in a pressure controlled mode, at a rate of 35 /min, I/E ratio 1:2 and Fi02 = 1. Different ventilator pressures 
were applied: P peak = 15 em HzO (15 /0), P peak = 20 em H20 (20 /0) or P peak = 25 em HzO with PEEP = 
4 em HzO (25/4). * p < 0.05, vs 15/0. 
At this stage during the course of the infection, criteria for treatment were not met and 
therefore surfactant was not injected. Twelve hours later (48 h after infection), six 
animals had died spontaneously and five animals died during ventilation at 15/0. 
Therefore, immediately after tracheotlxy, higher airway pressures were applied but 
reduced Pa02 {101.8 ± 20.7 (20/0, n=22) and 123.7 ± 34.1 (25/4, n=22), respectively} 
persisted. These animals were then randomly assigned to three groups. Before treatment 
there existed no significant differences in Pa02, PaC02, arterial pH and arterial 
bicarbonate concentrations (HC03.) between these groups (table 2). 
Five minutes after surfactant instillation, P a02 and pH had already significantly increased 
(figure 1) while PaC02 decreased significantly below pretreatment values. During the 
entire observation period, Pa02 in the surfactant treated group was significantly higher 
than in the saline group and in untreated controls. At the end of the observation period 
(2 h after treatment) Pa02 in the surfactant treated group had increased fourfold 
compared with pretreatment values. Pa02 values in the saline group and the untreated 
control groups increased slightly during the 2 h ventilation period. These increases, 
however, were not statistically significant. 
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Figure 1. Pa02 values (mean ± SD) 48 h after infection with a lethal dose of Sendai virus, during artificial 
ventilation and after treatment with surfactant (solid line, n=9), saline (broken line, n=7) or respiratory 
support only (dotted line, n=6). Animals were paralyzed (pancuronium bromide 0.1 mg/kg i.m.) and 
mechanically ventilated with a Siemens 900c ventilator, in a pressure controlled mode, at a rate of 35 /min, 
1/E ratio 1:2 and Fi02 = 1. Different ventilator pressures were applied: P peak = 20 em H20 (20/0) or P peak 
= 25 em H20 with PEEP = 4 em H20 (25/4). Treatment with surfactant or saline was done at 25/4 
ventilatory pressures and ventilator settings were kept unchanged during the entire observation period. * p 
< 0.05, surfactant treated animals vs saline treated and untreated controls, Mann-Whitney U test.# p < 0.05, 
vs pretreatment values at the same ventilator settings (25/4). 
In the surfactant treated group and in both control groups P a C02 decreased and pH 
concurrently increased during the observation period, whereas PaC02 reached 
physiological values in the surfactant treated group only and pH did not reach normal 
values (table 2). There were no significant differences in PaC02 or pH between the 
surfactant treated group and control groups. 
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Histological examination of rat lungs infected with Sendai virus (figure 2a) showed 
swelling of the alveolar walls and alveolar edema containing inflammatory cells. 
Furthermore, swelling of bronchial epithelial cells and atelectatic areas were present. 
Examination of lungs of infected animals 2 h after surfactant administration showed 
clearly improved lung aeration compared to the saline group and untreated controls 
(figure 2b and c). 
Table 2. 
Before After treatment 
PaC02 20/0 25/4 5min 60min 120 min 
(mmHg) 
surfactant 105.8 95.1 61.9 # 46.9 # 42.6 # 
n=9 (57.0) (43.6) (14.9) (8.2) (8.3) 
saline 74.5 76.7 68.1 49.2 # 54.6 
n=7 (21.0) (17.6) (21.2) (12.7) (15.9) 
untreated 122.9 97.6 80.4 63.7 # 55.9# 
n=6 (27.1) (23.2) (11.3) (5.3) (7.3) 
Before After treatment 
pH 20/0 25/4 5min 60min 120 min 
surfactant 7.13 7.12 7.22 # 7.33 # 7.33 # 
n=9 (0.18) (0.16) (0.09) (0.06) (0.11) 
saline 7.22 7.19 7.22 7.32 # 7.31 
n=7 (0.11) (0.11) (0.14) (0.08) (0.09) 
untreated 7.03 7.09 7.13 7.23 7.29 # 
n=6 (0.05) (0.07) (0.04) (0.03) (0.03) 
PaC02 and pH values, mean (SD), 48 h after infection with a lethal dose of Sendai virus, during artificial 
ventilation and after treatment with surfactant, saline or respiratory support only. Animals were mechanically 
ventilated with a Siemens 900c ventilator, in a pressure controlled mode, at a rate of 35/min, I/E ratio 1:2 
and Fi02 = 1. Different ventilator pressures were applied: P peak = 20 em H20 (20/0) or P p~ak = 25 em H20 
with PEEP = 4 em H20 (25 /4). Treatment with surfactant or saline was done at 25/4 ventilatory pressures 
and ventilator settings were kept unchanged during the entire observation period. * p < 0.05, surfactant 
treated animals vs saline treated and untreated controls, Mann-Whitney U test.# p < 0.05, vs pretreatment 
values at the same ventilator settings (25/4). 
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DISCUSSION 
One of the main functions of the alveolar surfactant system is prevention of end-
expiratory collapse of alveoli and small airways (23, 24). Furthermore, the surfactant 
system is essential for balancing lung water content. Pulmonary injury that impairs 
surfactant production or disturbance of the arrangement of phospholipids and surfactant-
associated proteins in the alveolar lining, may, therefore, result in pulmonary edema. 
Clements predicted in the early Sixties, that, on theoretical grounds, alveolar surfactant 
plays an important role in the prevention of pulmonary edema (25) and later 
experimental studies clearly demonstrate that dysfunction of the surfactant system causes 
pulmonary edema (26, 27). 
Findings in the present study suggest that surfactant deficiency is also an important factor 
in the pathogenesis of respiratory insufficiency due to Sendai virus pneumonia. Thirty-six 
hours after infection, animals show respiratory insufficiency which could only be 
overcome by a combination of high ventilatol)" peak airway pressure and PEEP. These 
ventilator settings almost completely restored blood gas to tensions to normal. However, 
that end-expiratory pressure - i.e. PEEP - is necessary to prevent alveolar collapse 
indicates the presence of surfactant deficiency 36 h after infection with Sendai virus. 
The decreased thorax-lung compliance two days after infection (19) and our present 
findings that gas exchange can be restored to near normal 48 h after infection by 
exogenous surfactant are further confirmation of the surfactant deficiency in the presence 
of Sendai virus-induced ARDS. 
The surfactant deficient state observed during Sendai virus pneumonia can be explained 
in several ways. In viral pneumonia, quantitative surfactant deficiencies are most likely 
to occur secondary to type II cell destruction (16). Destruction of type II cells by the 
inflammatory reaction to Sendai virus or by virus replication itself may result in depletion 
of surfactant stores in type II cells and decreased surfactant production by type II cells. 
Qualitative surfactant deficiency may result from biophysical inhibition of the surfactant 
material in the alveolar space. Protein rich edema fluid accumulated in the alveoli of 
infected animals contains potent inhibitors of the surfactant system, including plasma 
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proteins and red blood cell components. Studies on biophysical inhibition of surfactant 
activity have demonstrated that whole serum, hemoglobin and serum proteins such as 
albumin and fibrinogen can inhibit the function of lung surfactant (28-33). From these 
studies, it is clear that protein-induced inhibition of surfactant activity is enhanced by low 
surfactant concentrations. This indicates that the surfactant system in an already 
surfactant deficient lung - i.e. a surfactant deficiency as a result of destruction of type II 
cells by Sendai virus - is especially at risk for biophysical inhibition of surfactant function 
by the constituents of the alveolar exudate. 
Loss of surface active material from the alveolar space via lymphatics or directly into the 
bloodstream may occur when the integrity of the alveolar-capillary membrane is lost 
during viral pneumonia. Normally, little surface active material is lost from the lung in 
this manner, but this situation might change when the alveolar epithelium is disrupted 
in the presence of lung injury (11, 34, 35). Furthermore, loss of surfactant-associated 
proteins by leakage from the alveoli or breakdown of surfactant -associated proteins 
during the inflammatory reaction to Sendai virus will seriously disturb surfactant function 
as these proteins are indispensable for proper functioning of the surfactant system (36-
40). 
One of the main goals in treatment of ARDS patients, adequate arterial and tissue 
oxygenation, can often be achieved by artificial ventilation with PEEP and increased 
inspiratory oxygen concentrations. In this study, increased ventilatory airway pressures 
plus PEEP could maintain arterial oxygenation for at least 36 h after infection with the 
applied ventilator settings. 
After 48 hours, however, high inspiratory peak pressures together with PEEP (25 / 4) 
resulted in only minor (20%) increases in P.02 (n=22), compared with low inspiratory 
peak pressure without PEEP (15/0). This can be explained by alveolar collapse resulting 
from increased intrapulmonary surface tensions. Higher peak-airway pressures are 
needed to open up the lungs and a PEEP of 4 em H20 is not high enough to prevent 
end-expiratory collapse, demonstrating the small benefits of the applied ventilatory 
strategy. 
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Instillation of surfactant almost instantaneously increased Pa02 significantly (320% 
increase within 5 min) and during subsequent 2 hours of observation Pa02 increased even 
further. In the saline and in the nontreated control groups Pa02 gradually increased 
whereas PaC02 gradually decreased during the observation period, probably due to the 
application of PEEP. 
Our fmdings indicate that, initially, a surfactant deficient state and resulting hypoxemia 
in the acute phase of viral pneumonia can be overcome by application of PEEP. In a 
later stage of the disease, however, a higher airway peak-airway pressure with PEEP has 
no significant effects because the opening pressure of the lungs is increased. Intratracheal 
instillation of exogenous surfactant, however, reduces the opening pressure, prevents 
alveolar collapse and, combined with ventilatory support, restores gas exchange to almost 
normal. 
We conclude that lethal infection with Sendai virus in rats results in a surfactant 
deficiency of the lungs, which, initially, can be treated with respiratory support with high 
peak airway pressures and PEEP. When respiratory insufficiency is fully developed, 
artificial ventilation at high airway pressures with PEEP is not sufficient to restore gas 
exchange. At this stage of the disease, however, intratracheal instillation of exogenous 
surfactant can almost completely restore gas exchange to normal. 
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Figure 2a. Rat lung 48 h after infection with Sendai virus shows pneumonitis, interstitial swelling, alveolar 
exudate and atelectasis. Before fixation, lungs were inflated at a pressure of 20 em H20. Original 
magnification x 120, Hematoxylin/eosin staining. 
Figure 2b. Rat lung 48 h after infection with Sendai virus and 2 h after treatment with surfactant and artificial 
ventilation at 25/4. Before fixation, lungs were inflated at a pressure of 20 em H20. Original magnification 
x 120, Hematoxylin/eosin staining. 
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Figure 2c. Rat lung 48 h after infection with Scndai virus and 2 h after treatment with saline and artificial 
ventilation at 25/4. Before fixation, lungs were inflated at a pressure of 20 em H20. Original magnification 
x 120, Hematoxylin/eosin staining. 
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Chapter IX 
SURFACTANT REPlACEMENT THERAPY IMPROVES LUNG 
COMPLIANCE AND FUNCTIONAL RESIDUAL CAPACITY IN 
ENDSTAGE INFLUENZA A PNEUMONIA IN MICE 
SUMMARY 
Surfactant replacement therapy may be a promising approach for treatment of 
respiratory failure caused by virus pneumonia. This study in mice demonstrates that 
during the development oflethal influenza A pneumonia, thorax-lung compliance (C/kg) 
and functional residual capacity (FRC/kg) significantly decrease (28% and 54%, 
respectively) whereas lung water content significantly increases (25%). Furthermore, 
surface tension of broncholaveolar lavage fluid significantly increased, indicating loss of 
pulmonary surfactant. Surfactant replacement therapy during the endstage of pneumonia 
significantly increased C/kg by 31% and FRC by 21%. Instillation of solvent in control 
animals did not significantly affect pulmonary compliance (5% decrease) but significantly 
decreased FRC (25% decrease). Further, a new method for postmortem measurement 
of FRC in small laboratory animals - based on Archimedes' principle - is presented. 
INTRODUCTION 
Severe damage to the alveolar-capillary membrane caused by influenza A virus infection 
can lead to pulmonary edema, hemorrhage and death from respiratory failure and shock 
[1, 2]. Injury of type II cells decreases synthesis and excretion of surfactant [3, 4]. 
Therefore, disturbance of the pulmonary surfactant system may be an important factor 
in the etiology of respiratory failure during viral pneumonia, which might be treated by 
surfactant replacement therapy. If exogenous surfactant could restore lung mechanics in 
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influenza A virus pneumonia it may be a promising approach for treatment of respiratory 
failure caused by virus infection. 
To appropriately evaluate the effect of surfactant replacement on lung mechanics it is 
essential to measure thorax-lung compliance (C,1) and functional residual capacity 
(FRC). In most studies on the effect of surfactant replacement in animals with 
respiratory failure [for review see 5] FRC was not determined because an effective 
method for measuring FRC in small laboratory animals was not available. In this study 
we report the effects of lethal influenza A pneumonia in mice on Cu, FRC and surfactant 
activity in bronchoalveolar lavage (BAL) fluid, and the effects of surfactant replacement 
on Cu and FRC in endstage influenza A pneumonia. Further, a simple method for 
postmortem measurement of FRC in small laboratory animals is described. 
MATERIALS AND METHODS 
Eighty animals were randomly divided into 10 groups (scheme 1, n=8/group). Two 
groups served as controls, whereas eight groups were infected with a lethal dose of 
influenza A virus. In the control groups and in infected animals on the first, third and 
fifth day after infection the following protocol was executed. Bronchoalveolar lavage 
(BAL) was performed in one group for measurement of surface tensions of BAL fluid 
whereas in a second group C,b postmortem FRC and the lung wet/ dry weight ratios were 
measured (ratiOw;ct)· Furthermore, on the fifth day after infection, in the two remaining 
groups Cu was registered before and 10 min after intratracheal instillation of 0.15 ml 
surfactant or solvent. In these groups, postmortem FRC was obtained after the second 
registration of Cu. 
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Scheme 1. Experimental setup. 
controls day 1 day 3 day 5 day 5 
BAL BAL BAL BAL surfactant, 
FRC,Cn 
controls day 1 day3 day 5 dayS 
~11 FRC, Cn,FRC, ~" FRC, ctb FR~, solvent, FRC, 
ratiaw1d ratiowfd ratiaw1d ratiaw1d Cn 
Animals 
Male Swiss-bred mice (6-8 weeks old, SPF, obtained from Harlan/CPB, Zeist, The 
Netherlands) were used. Animals were housed under conventional conditions; water and 
food were given ad libitum. Infected animals were housed under the same conditions in 
a separate facility. Animals were kept under close surveillance and body weight (BW) 
was registered on the day of infection and on the day of the actual measurements. 
Infection procedure 
Influenza virus (A/PRS/34, H1N1) was passed once in 10 day embryonated chicken eggs. 
The allantoid fluid was clarified by centrifugation and stored at -70° C. The stock 
solution was diluted in sucrose and had a hemagglutination (HA) titer 1:400. 
Animals were exposed once for 30 min to nebulized live virus suspension (8x dilution in 
PBS of stock solution) in a llliter multichamber aerosol box [6]. Aerosol with a flow 
of 5 ljmin, particle size 0.6-2 J.lm [7], was produced with an Ultravent nebulizer 
(Ultravent, Malinckrodt Diagnostica, The Netherlands). 
Thorax-lung compliance (Cn) 
For measurement of Ctb animals were anesthetized by intraperitoneal injection of 
pentobarbital (40 mg/kg, Nembutal•, Algin BV, Maassluis, The Netherlands) and 
tracheostomized, using a metal cannula as tracheal tube. Animals were paralyzed by 
intramuscular injection of 0.05 ml pancuronium bromide (Pavulon•, Organon Technika, 
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Boxtel, The Netherlands), transferred to a multichambered body plethysmograph [for 
details see 8] heated to 38° C, and connected to a ventilator system for pressure-
controlled ventilation. The initial ventilator frequency was set at 30/min, 1/E ratio 1:2, 
peak pressure 25 em H 20 (25 /0) and Fi02 = 1; the mice were ventilated under these 
circumstances for 10 min to allow stabilization. Then Cu was recorded at frequency 
10/min. For calculation of compliance per kg BW (Cu/kg), BW registered on the day of 
infection was used. 
Postmortem FRC measurement 
After registration of C1b the animals were killed with an overdose of pentobarbital and 
skinned. The thorax was prepared free, carefully leaving the diaphragm intact, whereas 
the intratracheal cannula was left in place. After this procedure the lungs were 
reexpanded with 0.5 ml of air to reopen atelectatic areas induced by the surgical 
procedure. Next, the lungs were connected for 10 min to 100% nitrogen at a pressure 
of 5 em H 20 to allow for absorption of the remaining oxygen in the lungs. The trachea 
was then bound and the metal cannula removed, maintaining the positive pressure of 5 
em H 20 in the lungs. 
First the total weight (W) of the thorax was registered and then the thorax was immersed 
in saline at a preset depth to measure the upward force (F) caused, according to 
Archimedes' principle, by displacement of a volume of saline. FRC was calculated by the 
following formula·: 
FRC = 0.99 * F - 0.94 * W 
For calculation of the FRC per kg BW (FRC/kg), BW on the day of infection was used. 
After the FRC measurement, the lungs were excised for determination of the rati<>w;d· 
Dry lung weight was obtained after drying the lungs in a conventional microwave oven 
at 250 W for 1 h [9]. 
• For deductive procedure of FRC formula see Appendix. 
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Bronchoalveolar lavage (BAL) and surface tension measurement 
BAL was performed three times with a volume of 1 ml sterile saline preheated to 38° C 
(total volume 3 ml, recovery 2.3 ± 0.2 ml). BAL cells were removed from the lavage 
fluid by centrifugation (800 x g, 10 min at 4° C). Surfactant activity in BAL fluid was 
measured with a modified Wilhelmy balance (E. Biegler GmbH, Mauerbach, Austria) 
by applying 400 1-11 of BAL fluid onto a 71.3 cm2 trough. For measurement of minimal 
surface tensions the area was compressed to 20% of the initial value. 
Surfactant/solvent instillation 
On the fifth day after infection one group received treatment with surfactant and one 
group was sham-treated with solvent. 
After measurement of Ctl as described above, a positive end-expiratory pressure of 4-5 
em H20 was introduced; the rest of the ventilator settings was kept unchanged. Next, 
0.15 ml of a natural bovine surfactant (200 mgjkg BW solved in 1:2 mixture of H20 and 
saline) extracted in basically the same manner as described by others [10] or 0.15 ml 
solvent (1:2 mixture of H20 and saline) was instilled into the lungs. A period of 10 min 
was allowed for stabilization and Ctl was registered again. After the second registration 
of Ctb FRC was measured as described above. 
After the experiment, the chest of each animal was opened and a cannula was inserted 
into the right ventricle. The pressure of 5 em H20 in the lungs was maintained while the 
lungs were perfused with formalin ( 4%) via the right ventricle. After perfusion, the lungs 
were removed and kept in formalin (10%) for at least 48 h. Paraffm sections were 
stained with hematoxylin and eosin and examined microscopically. 
Statistical analysis and presentation of data 
Statistical analysis of data was performed using the Mann-Whitney U test for analysis of 
intergroup differences or the Wilcoxon test for analysis of intragroup differences. 
Statistical significance was accepted at p ~ 0.05 (two-tailed). All data are expressed as 
mean± SD. 
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RESULTS 
From the third day after infection on, animals showed significant loss of BW (Table 1) 
and suffered from clinically manifest illness displaying ruffled furs, difficulties with 
moving and audible breathing difficulties. 
Cu/kg and FRC/kg (Table 1) were significantly decreased on the third and the filth day 
after infection. 
Surfactant replacement on the fifth day after infection (Table 2) significantly increased 
both Cu/kg (compared to values obtained before instillation) and FRC/kg (compared 
to animals on the fifth day after infection, not receiving treatment with surfactant or 
solvent). Solvent instillation did not significantly change Cu/kg (compared to values 
obtained before instillation). However, solvent instillation significantly reduced FRC/kg 
compared to animals on the fifth day after infection receiving no treatment, and 
surfactant treated animals (Table 2). Furthermore, both minimal and maximal surface 
tension of BAL fluid (Table 1) were significantly increased on the fifth day after infection 
compared to control values, indicating significant loss of surfactant activity. RatiOw;d was 
significantly increased on ~he third and fifth day after infection, compared to healthy 
controls (Table 1). 
Histological examination of mouse lungs five days after infection with influenza A virus 
showed severe atelectasis and alveolar filling with leukocyte rich exudate. Histological 
examination of surfactant treated lungs shows clearly improved lung aeration compared 
to the solvent treated lungs (Figures 1A and lB). 
DISCUSSION 
Influenza A virus pneumonia is characterized by permeability edema caused by 
disruption of the integrity of the alveolar-capillary membrane [11]. Pulmonary edema, in 
this study reflected by increased Rati0w1d, was associated with decreased pulmonary 
compliance, decreased FRC and decreased surfactant activity in BAL fluid; findings 
which are confirmed by other studies on pneumonia-induced pulmonary edema [12-19]. 
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Table 1. 
Days after infection 
controls 1 3 5 
Change ofBW +55 -10.4 • -21.1 • 
(%) (2.2) (15) (1.6) 
Rw/d 4.28 4.21 4.83. 5.34. 
(051) (0.22) (0.28) (0.78) 
FRC/kg 20.8 20.0 14.1. 95. 
(ml/kg) (25) (2.1) (2.4) (3.3) 
CtJkg 057 056 0.46. 0.41. 
(ml/kgfcm H20) (0.08) (0.06) (0.06) (0.14) 
Maximal surface 58.3 585 555 63.9. 
tension (dynes/em) (3.7) (4.2) (6.6) (1.7) 
Minimal surface 225 21.6 21.1 32.2. 
tension (dynes/em) (1.7) (1.4) (3.3) (2.1) 
Body weight (BW) changes, functional residual capacity (FRC/kg) at 5 em H20, thorax-lung compliance 
(Cu/kg) and lung wet/dry weight ratio (Rw/d) of control mice and mice infected with lethal dose influenza 
A virus. Mean (SD), n = 8/group. • = p!:: 0.05, Mann-Whitney U test. 
Impaired lung function during pulmonary edema can be explained by impairment of the 
surfactant function by edema constituents. Constituents like albumin, fibrinogen and 
other plasma components are potent inhibitors of the surfactant system [20-25]. 
Impaired surfactant function will lead to decreased lung distensibility and collapse of 
alveoli and small airways leading to atelectasis, enlargement of the right-to-left shunt due 
to perfusion of non-ventilated alveoli, hypoxemia and acidosis [26-28]. Furthermore, the 
surfactant system itself is essential for stabilization of the fluid balance in the lung and 
for prevention of pulmonary edema [29-31]. In general, alveolar flooding will not occur 
as long as the suction force in the pulmonary interstitium exceeds the pressure gradient 
generated by surface tension in the alveolar air-liquid interface [32]. 
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Table 2. 
Surfactant group Solvent group 
Before After Before After 
C1Jkg 0.34 0.52 * 0.35 0.32 
(ml/kg/cm Hp) (0.15) (0.28) (0.14) (0.15) 
Healthy Healthy Untreated Surfactant Solvent 
corrected dayS treated treated 
dayS dayS 
FRC/kg 20.8 14.7 9.5 14.0 #,$ 4.3 
(ml/kg) (0.04) (2.2) (3.3) (2.3) (1.9) 
Influence of surfactant or solvent instillation on thorax-lung compliance (Cu/kg) and postmortem functional 
residual capacity (FRC/kg) on the fifth day after infection with lethal dose influenza A virus. Cu/kg at 25 em 
H20, before and 10 min after instillation of 0.1S ml surfactant or solvent. * = p < O.OS, compared to values 
before treatment, Wilcoxon test. FRC/kg at S em H20, after instillation of surfactant or solvent. # = p :!: O.OS 
compared to solvent treated group, $ = p :!: O.OS compared to untreated animals at the fifth day after 
infection, Mann-Whitney U test. n = 8/group. 
Inhibition of the surfactant function by edema constituents therefore accelerates the 
formation of pulmonary edema and the development of respiratory failure, resulting in 
a vicious circle of surfactant inactivation and loss of pulmonary function. Another 
explanation for decreased surfactant function in this study is that influenza A virus 
infection leads to destruction of type II cells followed by a deficit of surfactant [3] which 
inevitably leads to the observed decreased compliance, FRC and pulmonary edema as 
described above and in other studies [4, 33]. 
From this study it cannot be concluded at which stage during the infection impairment 
of surfactant function significantly contributes to changes in pulmonary mechanics. 
Increased surface tension of BAL fluid on the fifth day after infection clearly indicates 
decreased surfactant function. This can be caused by loss of surfactant or by inhibition 
of surfactant. The fact that in vitro surface tension of BAL fluid was not changed on the 
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third day after infection, despite changes in lung mechanics, does not necessarily mean 
that impairment of surfactant function was not present in vivo. 
It is conceivable that the inhibitory action of plasma proteins was diminished during 
measurement of surface tension with the Wilhelmy balance. Application of a small 
quantity of BAL fluid to the water phase of the Wilhelmy balance trough may have 
caused dissociation of the binding of inhibitory proteins to surfactant. 
Surfactant substitution on the fifth day after infection restored CrJkg of infected animals 
almost to normal (from 60% of non-infected control values before substitution to 91% 
after surfactant substitution), which confirms preliminary data obtained in mice with 
influenza A pneumonia [33]. Instillation of solvent did not significantly affect Cu (from 
61% of non-infected control values before to 56% after instillation). Surfactant treatment 
also significantly improved FRC. 
FRC/kg of infected animals on the fifth day after infection was 46% of non-infected 
control values. FRC/kg of the surfactant treated group was 67% of non-infected control 
values whereas FRC/kg in the solvent group was only 21% of non-infected control 
values. FRC was not completely restored to control values by surfactant. 
One reason for this could be that instillation of 0.15 ml surfactant or solvent leads to 
filling of the FRC with fluid, resulting in a 0.15 ml decrease of FRC. Therefore, to take 
into account the effect of instillation of a certain amount of fluid 0.15 ml should be 
subtracted from control FRC values (or added in treated animals) to correct for the 
reduction of FRC by the volume of the instilled dose (assuming that no resorption of 
fluid takes place). If 0.15 ml is subtracted from control FRC/kg values (20.8 ± 0.04 ml), 
the corrected FRC/kg (FRC'/kg) in control animals becomes 14.7 ± 2.2 ml. FRC/kg 
of infected animals after surfactant or solvent instillation becomes then 95% and 29% 
of FRC' /kg, respectively. 
The postmortem method for measurement of FRC as described in this study is highly 
reproducible and gives an accurate estimation of postmortem FRC, taking into account 
factors like body size, sex, age and, last but not least, the existence of lung disease. 
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Figure 1 A. Mouse lung 5 days after infection with influenza A virus and after treatment with surfactant and 
artificial ventilation at 25/4. Before fixation, lungs were inflated with pure nitrogen at a pressure of 5 em H20. 
Original magnification x 240, Hematoxylin/eosin staining. 
Figure 1 B. Mouse lung 5 days after infection with influenza A virus and after treatment with solvent and 
artificial ventilation at 25/4. Before fixation, lungs were inflated with pure nitrogen at a pressure of 5 em H20. 
Original magnification x 240, Hematoxylin/eosin staining. 
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However, with this postmortem method, several factors that have profound influence on 
FRC in vivo, like posture, diaphragmatic muscle tone and blood content of the thorax 
are not taken into account. We opine, however, that the method is suitable for routine 
use in laboratory animals because of its simplicity and accuracy. 
Findings in this study indicate that reduced pulmonary compliance and FRC caused by 
loss of surfactant function during viral pneumonia can almost completely be restored by 
surfactant replacement therapy, which is indirect proof for a shortage of surfactant during 
influenza A pneumonia. 
In the winter of 1989/90 the influenza A epidemic caused 4100 excess deaths in the 
Netherlands (0.3 per 1000 population) whereas in the same period in the UK 7.700 
patients died from pneumonia, of which 2440 were certified as being due to influenza [34, 
35]. During the influenza epidemic of 1957 a close relationship between the degree of 
hypoxia and survival of severe influenza! pneumonia was observed [1, 2]. It is therefore 
desirable to further investigate the possibilities for restoring lung function during 
respiratory failure caused by viral or bacterial pulmonary infection. Based on findings in 
this study, we opine that surfactant replacement therapy seems a promising approach for 
the treatment of respiratory failure during viral pneumonia. 
Summarizing, we conclude that influenza! pneumonia in mice is associated with increased 
lung water content and decreased pulmonary mechanics, including FRC, supposedly 
caused by disturbance of the integrity of the aveolar-capillary membrane and decreased 
function of the surfactant system. Surfactant replacement therapy can almost completely 
restore both Cn and FRC, which will inevitably lead to improved gas exchange. These 
observations indicate that surfactant replacement therapy is a promising approach in the 
treatment of respiratory failure due to viral pneumonia. 
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APPENDIX 
The formula for the calculation of FRC is based on Archimedes' principle that a body 
immersed in a fluid is subject to an upward force equal in magnitude to the weight of 
fluid it displaces. 
The denotations in the equations are defmed as follows: 
FRC 
w 
w 
F 
v 
Dsa~ 
the volume in the lungs filled with pure nitrogen at a pressure of 5 em 
HP 
the "dry" weight of the thorax 
the presumed weight of the thorax as if it were made up of massive 
tissue, the FRC not containing air but tissue 
the force exerted by the saline on the thorax, when immersed in saline 
at a preset depth 
the volume of the thorax 
the density of saline (1.009) 
the density of tissue (1.07) [36] 
Two assumptions are made: 
1) 
2) 
F = V * D •• 1 and 
w = V * Dtiss· 
Subtraction of W from w gives the weight of the FRC as if it were made up from 
massive tissue: 
3) w - W = FRC * Dtiss 
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Substitution of equation 2 into equation 3 gives: 
4) V * Duss - W = FRC * D1iss, 
which can be rearranged by inserting equation 1 to give: 
5) F /Dsai * Dtiss - W = FRC * Dtiss· 
Substituting Dsal = 1.009 and Duss = 1.07 gives: 
6) F * 1.06 - W = FRC * 1.07, 
which can be rearranged to give: 
7) FRC = 0.99 * F - 0.94 * W. 
Both F and W can easily be measured with a conventional balance. 
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CHAPTER X 
SUMMARY AND CONCLUSIONS 
PART I. ORAL IMMUNIZATION 
Van der Heijden ended his thesis' on immunoglobulin production in the intestine of 
mice by concluding that it must be possible to use the immune compartment of the 
intestine to induce protective immunity at the mucosae by means of safe vaccines containing 
non-replicating antigens. This thesis and other studies on oral immunization (for overview 
see chapter 2 of this thesis) confirm his statement. In chapter 3 it was demonstrated that 
survival of mice after intranasal inoculation with S. pneumoniae could significantly be 
enhanced by previous oral administration of a polyvalent bacterial lysate. Although it is 
conceivable that increased sigA production in the respiratory tract after oral 
immunization is involved in this protective effect, this is not proven by this study because 
sigA was not measured. Furthermore, it is conceivable that enhanced nonspecific 
immune mechanisms are involved in the protection against respiratory pathogens after 
oral immunization. In chapter 4 it is reported that oral immunization not only reduces 
the pulmonary inflammatory reaction to infection with S. pneumoniae but also enhances 
T -cell activity, expressed as increased interferon-gamma concentrations m 
bronchoalveolar lavage fluid. The fact that enhancement of nonspecific immune 
mechanisms by oral immunization can indeed result in significant protection against 
respiratory pathogens is confirmed in chapter 5. This chapter reports that oral 
immunization with a polyvalent bacterial lysate results in effective protection against 
aerolized influenza A virus infection. It can be concluded from this study that T -cells and 
alveolar macrophages play an important role in the protection against influenza A virus, 
achieved by oral immunization. Summarizing, it is concluded from the first part of this 
* Van der Heijden PJ. Quantitative aspects of immunoglobulin production in the 
intestine of mice. Thesis, Erasmus University Rotterdam 1990. 
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thesis that oral administration of a polyvalent bacterial lysate in mice can induce effective 
protection against bacterial and viral respiratory infection. 
PART II. SURFACTANT REPLACEMENT THERAPY 
In chapter 6 a short introduction to the pulmonary surfactant system and surfactant 
replacement therapy is given. To evaluate surfactant replacement therapy for the 
treatment of ARDS, experimental models are required that demonstrate as many 
characteristic features of ARDS as possible. Chapter 7 presents a new model of ARDS 
in rats, induced by Sendai virus infection. Preliminary results obtained in two animals 
indicate a positive effect of surfactant replacement therapy on arterial oxygenation. 
Subsequently, chapter 8 presents the results of a study on surfactant replacement in 
terminally-ill rats suffering from respiratory failure induced by Sendai virus infection. In 
the endstage of the pneumonia, gas exchange was severely impaired and arterial 
oxygenation was refractory to increased ventilatory pressures with PEEP. At this stage, 
however, exogenous surfactant induced a significant increase in arterial oxygen tension 
within five minutes after instillation, whereas no significant increase was observed in the 
control groups. In this study we did not investigate the effects of surfactant replacement 
therapy on pulmonary mechanics, because at that time no suitable technique for 
measurement of functional residual capacity (FRC) in small laboratory animals was 
available. Therefore, in chapter 9 a new technique, based on Archimedes' principle, is 
introduced for measurement of postmortem FRC in small laboratory animals. Chapter 
9 reports that lethal influenza A virus infection results in a significant decrease in thorax-
lung compliance, FRC and pulmonary surfactant paralell with a significant increase in 
lung water content. Further, it is demonstrated that surfactant replacement therapy at 
endstage pneumonia significantly improves thorax-lung compliance and FRC whereas 
in the control group thorax-lung compliance was not changed, but FRC was significantly 
decreased by instillation of solvent. 
Summarizing, it is concluded from the second part of this thesis that experimental viral 
pneumonia may lead to severely decreased lung mechanics with impaired gas exchange. 
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Further, that in the terminal stage of viral pneumonia surfactant replacement therapy can 
almost completely restore lung mechanics and gas exchange and is, therefore, a 
promising approach for the treatment of respiratory failure caused by viral pneumonia. 
SAMENV ATIING EN CONCLUSIES 
DEEL I. ORALE IMMUNISATIE 
Vander Heijden besloot zijn proefschrift• over immunoglobulinen produktie in de darm 
van de muis met de konklusie dat het in principe mogelijk moet zijn het 
immuunkompartiment van de dann te gebrniken om beschennende immuniteit aan de 
mucosae te induceren middels veilige vaccins die niet-replicerende antigenen bevatten. Dit 
proefschrift en ander onderzoek naar orale immunisatie (voor overzicht zie hoofdstuk 
2 van dit proefschrift) bevestigen deze stelling. In hoofdstuk 3 wordt aangetoond dat de 
overleving van muizen, die in de neus zijn geinfekteerd met S. pneumoniae, signifikant 
verbeterd kan worden door voorafgaande orale toediening van een polyvalent 
bakterielysaat. Alhoewel het redelijk is te veronderstellen dat een verhoogde sigA 
produktie in de luchtwegen na orale immunisatie betrokken is bij het tot stand komen 
van dit beschermende effekt, wordt dit niet aangetoond in deze studie omdat sigA niet 
is gemeten. Verder is het redelijk om aan te nemen dat versterking van niet-specifieke 
immuunmechanismen een rol spelen in de bescherming tegen respiratoire pathogenen 
waargenomen na orale immunisatie. In hoofdstuk 4 wordt beschreven dat orale 
immunisatie niet aileen de ontstekingsreaktie in de long na infektie met S. pneumoniae 
vermindert, maar ook de T-cel aktiviteit verhoogt, hetgeen tot uitdrukking komt in 
verhoogde interferon-gamma koncentraties in bronchoalveolaire lavagevloeistof. Dat door 
orale immunisatie versterkte niet -specifieke immuunmechanismen duidelijk bescherming 
bieden tegen respiratoire pathogenen wordt gedemonstreerd in hoofdstuk 5. In dit 
Van der Heijden PJ. Quantitative aspects of immunoglobulin production in the 
intestine of mice. Proefschrift, Erasmus Universiteit Rotterdam 1990. 
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hoofdstuk wordt beschreven dat orale immunisatie met een polyvalent bakterielysaat 
effektief bescherming biedt tegen infektie met een influenza A aerosol. Uit deze studie 
kan gekonkludeerd worden dat T -cell en en makrofagen een aktieve rol spelen in de 
bescherming tegen influenza A virus, bereikt door orale immunisatie. Samenvattend 
wordt uit het eerste gedeelte van dit proefschrift gekonkludeerd dat orale toediening van 
een polyvalent bakterielysaat aan muizen resulteert in een effektieve bescherming tegen 
bakteriele en virale luchtweginfekties. 
DEEL II. SURFACTANT VERVANGENDE BEHANDELING 
In hoofdstuk 6 wordt een korte inleiding gegeven over het surfactantsysteem van de long 
en over behandeling met surfactant. Om surfactant vervangende behandeling voor ARDS 
te evalueren zijn proefdierenmodellen nodig die zoveel mogelijk karakteristieken van 
ARDS vertonen. In hoofdstuk 7 wordt een nieuw ARDS-model in ratten gepresenteerd, 
met Sendai virus als veroorzaker. Voorlopige resultaten verkregen van twee dieren Iaten 
een positief effekt zien van surfactanttoediening op de arteriele oxygenatie. Vervolgens 
worden in hoofdstuk 8 de resultaten getoond van een studie naar de effekten van 
surfactanttoediening bij ratten in het eindstadium van een respiratoire insufficientie, 
veroorzaakt door Sendai virus. In het eindstadium van de longontsteking was de 
gasuitwisseling ernstig verminderd en het zuurstofgehalte van het arteriele bloed kon niet 
verbeterd worden door verhoging van de beademingsdrukken met gelijktijdig gebruik van 
PEEP. In dit stadium echter resulteerde surfactant toediening in een signifikante stijging 
van de arteriele zuurstofspanning, binnen vijf minuten na toediening, terwijl geen 
signifikante verbetering optrad in de kontrolegroep. In deze studie werd niet het effekt 
van toediening van surfactant op de longmechanika onderzocht, omdat op dat moment 
geen goede techniek beschikbaar was in ons laboratorium voor het meten van de 
funktionele residuele kapaciteit (FRC) in kleine proefdieren. Daarom wordt in hoofdstuk 
9 een nieuwe techniek geintroduceerd, gebaseerd op de Wet van Archimedes, voor het 
postmortem meten van de FRC in kleine proefdieren. In hoofdstuk 9 wordt getoond dat 
een lethale infektie met influenza A virus resulteert in een signifikante daling van de 
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thorax-long kompliantie, de FRC en het surfactant gehalte van de long, terwijl de 
hoeveelheid vocht in de long toeneemt. Verder wordt getoond dat behandeling met 
surfactant gedurende het eindstadium van de longontsteking resulteert in een signifikante 
verbetering van de thorax-long kompliantie en de FRC, terwijl in de kontrolegroep de 
thorax-long kompliantie niet verandert en dat de FRC zelfs signifikant verslechtert door 
toediening van het oplosmiddel. 
Samenvattend wordt uit het tweede deel van dit proefschrift gekonkludeerd dat virale 
longontstekingen in proefdieren leiden tot een sterke verslechtering van de 
longmechanika en een verstoorde gasuitwisseling. Verder, dat behandeling met surfactant 
in het eindstadium van een virale longontsteking de longmechanika en de gasuitwisseling 
bijna volledig kan herstellen. Behandeling met surfactant lijkt daarom een veelbelovende 
manier om respiratoire insufficientie veroorzaakt door een virale longontsteking te 
behandelen. 
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